Document:

EX-10.6

 Exhibit 10.6 

EXECUTIVE EMPLOYMENT AGREEMENT 

This EXECUTIVE EMPLOYMENT AGREEMENT (the “Agreement”), effective as of this 1st day of January 2015, is entered into by Conkwest, Inc., a Delaware corporation with its principal place of business at 2533 S. Coast Highway 101, Suite 210, Cardiff-by-the-Sea, CA 92007 (the
“Company”), and Barry J. Simon, M.D., an individual resident of California (the “Executive”). 

WHEREAS, the Company and the Executive entered into that certain Amended and Restated Executive Employee Employment,
Non-Disclosure and Confidentiality Agreement, dated as of March 19, 2008, as amended from time to time (the “Original Agreement”); 

WHEREAS, the Company [intends to file] a Form S-1 registration statement under the Securities Act of 1933 with the Securities
Exchange Commission and anticipates effecting an initial public offering of the Company’s common stock (the “IPO”); and 

WHEREAS, in connection with the anticipated IPO, the Company and the Executive deem it advisable and appropriate to replace
the Original Agreement with this Agreement; and 
 In consideration of the mutual covenants and promises contained in this
Agreement, and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged by the parties to this Agreement, the parties agree as follows: 

1. Employment/Duties. During the Employment Period (as defined below), the Executive shall serve as President and Chief
Executive Officer of the Company and shall have all the duties, responsibilities and authority commensurate with such position and such additional duties as may be determined by the Company’s Board of Directors (“Board of
Directors”). The Executive shall be based at the current location of his offices (Cardiff-by-the-Sea, California) and provided with office space and support personnel and equipment commensurate with his position. The Executive shall report
to, and be subject to the general supervision of, the Board of Directors, consistent with the terms of this Agreement. 

The Executive agrees to devote substantially all of his business time, attention and energies to the business and interests of
the Company during the Employment Period; provided, however, that the Executive may be permitted to engage in other activities consistent with past practice, including membership on boards of directors of other businesses or
non-for-profit organizations, so long as such activities do not materially interfere with the performance of the Executive’s duties under this Agreement and have been disclosed to and approved in advance by the Board of Directors. The
Executive’s service as a member on the board of directors of Inex Bio shall be deemed to have been disclosed and approved by the Board of Directors. The Executive agrees to abide by the rules, regulations, personnel practices and policies of
the Company, as adopted and amended from time to time by the Company, provided, that such rules, regulations, practices and policies are not inconsistent with the terms and conditions of this Agreement and have been disclosed in advance to
the Executive. 

  
 -1- 

 Further, during the Employment Period, so long as the Company’s common stock
is not publicly traded, Executive shall be a member of the Board of Directors (and all other boards of directors of subsidiaries of the Company) and, if the common stock of the Company becomes publicly traded, subject to the requirements of
applicable law (including, without limitation, any rules or regulations of any exchange on which the common stock of the Company is listed, if applicable), the Company shall cause the nominating and corporate governance committee of the Board of
Directors to propose to the shareholders of the Company at each annual meeting occurring during the Employment Period at which Executive is subject to election or re-election, as applicable, the election or re-election, as applicable, of the
Executive as a member of the Board of Directors and the Executive shall so serve if elected or re-elected; provided, however, that if the Executive’s employment with the Company terminates for any reason, the Executive’s
membership on the Board shall also terminate, unless otherwise agreed in writing by the Company and the Executive. 
 2.
Effective Date/Period of Employment. Executive’s employment with the Company commenced on May 21, 2007 (the “Original Effective Date”). Employment under this Agreement shall be effective as of January 1, 2015
(the “Effective Date”) and shall continue until terminated in accordance with the provisions of Section 4 (the “Employment Period”), subject to Section 9.13. 

3. Compensation and Benefits. 

3.1. Base Salary. During the Employment Period, the Company shall pay the Executive a base salary of $395,000
calculated on an annual basis (as increased, “Base Salary”), paid in periodic installments in accordance with the Company’s customary payroll practices. The Base Salary shall be increased by at least 6% annually, beginning at
the end of calendar year 2015, until termination as provided for herein. The Executive’s performance, the performance of the Company and such other factors as the Board of Directors deems appropriate, in its sole discretion, shall be considered
in such review. 
 3.2. Additional Compensation. 

(a) Annual Bonus Opportunity. During the Employment Period, the Executive may be eligible to receive an annual cash
bonus no later than sixty (60) days after the end of each calendar year, as determined by the Board of Directors (or the Compensation Committee of the Board of Directors (the “Committee”)) in its good faith discretion. The
bonus (if any) will be awarded based on objective or subjective criteria established by the Board of Directors (or the Committee) in good faith consultation with the Executive and with due regard to any performance or other metrics as the Executive
may propose [and agreed to by the Executive, such agreement not to be unreasonably withheld]. The Executive’s target bonus will be equal to 45% of the Executive’s Base Salary (the “Annual Bonus”), which amount shall not be
pro-rated for 2015. 
 3.3. Equity Compensation. 

(a) Existing Equity Grants. Pursuant to the Original Agreement, the Executive was granted a stock option to purchase
200,000 shares of the Company’s common 

  
 -2- 

 
stock on December 14, 2014 (the “Existing Equity Award”). Notwithstanding anything to the contrary in the Existing Equity Award, in the event the Executive’s employment
is terminated pursuant to Section 4.3 or 4.4 of this Agreement, all of the Executive’s outstanding Existing Equity Award shall become fully vested and such stock options underlying such Existing Equity Award shall remain outstanding and
exercisable (to the extent not already exercised) for a period of three (3) years, measured from (x) with respect to a Change of Control, the date of the consummation of the Change of Control, or if later, the date of the Executive’s
termination of employment and (y) with respect to any other event, the date of the Executive’s termination of employment. 

(b) IPO Equity Awards. Upon the closing date of the IPO (the “IPO Effective Date”), the following
equity awards shall be granted to the Executive pursuant to the Company’s 2014 Equity Incentive Plan (the “2014 Plan”: (i) a stock option to purchase 300,000 shares of common stock of the Company (the “IPO
Options”) with an exercise price equal to the fair market value of the Company’s common stock on the date of grant; and (ii) a grant of 200,000 restricted stock units representing the right to receive one share of the
Company’s common stock for each restricted stock unit that becomes vested (the “IPO RSUs” and together the with IPO Options, the “IPO Equity Awards”). The award agreement evidencing the grant of the IPO Equity
Awards shall provide that they vest 50% upon grant, and 50% upon the first anniversary of the IPO Effective Date, conditioned on the continued employment of the Executive as of the IPO Effective Date, subject to accelerated vesting as provided for
in this Agreement. The provisions of this Agreement with respect to the treatment of equity awards to the Executive upon termination of employment or Change of Control shall apply with respect to the IPO Equity Awards. Following the grant of the IPO
Equity Awards, the Executive shall remain eligible to receive subsequent grants of options, restricted stock units or other equity-based awards under the 2014 Plan or any successor plan thereto. 

(c) Future Annual Equity Grants. Commencing as of the first calendar year following the grant of the IPO Equity
Awards, or in the event that the IPO Effective Date does not occur and the IPO Equity Awards are not granted, the first calendar year during which this Agreement becomes effective, the Executive shall be eligible to receive additional equity grants
as determined by the Committee or the Board of Directors. The annual equity grants to the Executive during the Employment Period shall have a target value as of the grant date such that the aggregate target value of such annual equity grants, and
the Executive’s base salary and annual bonus at target, result in total direct compensation opportunity for the Executive for the applicable year at no less than $1,200,000 per calendar year of the Employment Period. 

3.4. Benefits and Perquisites. During the Employment Period, the Executive shall be entitled to participate in all
benefit programs that the Company makes available to its senior executives, and for so long as he remains employed, Executive shall remain eligible, consistent with past practices, for all perquisites and benefits for which he is currently eligible
as of the Effective Date. The Executive shall be entitled to take at least four (4) weeks of paid vacation (or such greater amount of vacation time as the Executive may qualify for consistent with the Company’s employee benefits policy) in
addition to customary business holidays available to the Company’s employees generally. Executive’s tenure with the Company for purposes of determining eligibility, payments and benefit levels under any Company benefit and welfare plan
shall be based on his service date from the Original Effective Date. 

  
 -3- 

 3.5. Reimbursement of Expenses. 

(a) The Company shall reimburse the Executive for all reasonable travel, entertainment and other expenses incurred or paid by
the Executive in connection with, or related to, the performance of the Executive’s duties, responsibilities or services on behalf of the Company under this Agreement, in accordance with policies and procedures, and subject to reasonable
limitations, adopted by the Company from time to time; provided that the Executive shall be entitled to business class airfare on domestic flights exceeding three (3) hours and first class airfare on all foreign flights. 

(b) The Company shall pay the reasonable attorney’s fees and out-of-pocket expenses of the Executive’s counsel
incurred in connection with the negotiation and subsequent interpretation of this Agreement. 
 3.6. Withholding.
All salary, bonus and other compensation payable to the Executive during the Employment Period shall be subject to applicable required deductions for state and federal withholding tax, social security and all other employment taxes and payroll
deductions. 
 3.7. Indemnification and D&O Insurance. The Company shall indemnify and hold Executive harmless
during his employment or service as a member of the Board of Directors (or both) to the maximum extent and provided under and subject to the terms of the Company’s charter and by-laws (as in effect as of the Effective Date, subject to any
improvements in coverage) and applicable law. During the Employment Period, and for a term of six years thereafter, the Company shall purchase and maintain, at its own expense, directors and officers liability insurance providing coverage for
Executive in the same amount as for members of the Board of Directors in respect of acts and omissions of the Executive in his capacity as such or as a director of the Company and occurring during Executive’s employment or service as a member
of the Board of Directors (or both). 
 3.8. Piggyback Registration Rights. Following any public offering by the
Company, and subject to any applicable underwriters’ lock up period, the Executive shall, with respect to his then owned common stock in the Company, be provided with piggyback registration rights in connection with any subsequent public
issuance or secondary sale of common stock, in each case on commercially reasonable terms. 
 4. Termination of
Employment Period. The employment of the Executive by the Company pursuant to this Agreement shall terminate upon the occurrence of any of the following: 

4.1. By the Company for Cause. At the election of the Company, for Cause, provided that prior to a termination of the
Executive’s employment pursuant to subsection (iii), below, the Executive shall have thirty (30) days to cure in all material respects such Cause event(s) following the Executive’s receipt of written notice by the Company, which
notice shall specifically identify the Cause upon which the termination is based and after the Executive has been given such notice. For the purposes of this Section 4.1, “Cause” means (i) the Executive’s conviction
of, or guilty plea to, a felony, (ii) the Executive’s commission of any crime involving 

  
 -4- 

 
fraud or material dishonesty in connection with the Executive’s employment by the Company, or (iii) the Executive’s willful and repeated failure to substantially perform his duties
to the Company or material breach of this Agreement, in each case after written notice to Executive and the failure to cure within thirty (30) days thereafter (unless such act or omission, by its nature, may not be remedied). No act or failure
to act shall be deemed “willful” for the purposes of this Agreement unless done, or failed to be done, by the Executive intentionally and in bad faith. Any termination for Cause shall be effected by a resolution of the majority of the
members of the Board of Directors. Prior to terminating the Executive’s employment for Cause, the Board of Directors shall deliver to the Executive, within ten (10) days after the occurrence of the act(s), omission(s), event(s) and/or
circumstance(s) purportedly constituting Cause hereunder, a written notice setting forth in sufficient detail the act(s), omission(s), event(s) and/or circumstance(s) the Board of Directors believe in good faith constitute Cause to terminate the
Executive’s employment. In the event the Board of Directors delivers to the Executive the notice described in the preceding sentence, the Executive shall be afforded an opportunity to meet with the Board of Directors with counsel of
Executive’s choosing, upon reasonable notice under the circumstances, and explain and defend any act(s), omission(s), event(s) and/or circumstances alleged by the Board of Directors in the written notice delivered to the Executive to constitute
grounds for a termination for Cause. If Executive has, and utilizes, such opportunity to be heard, the Board of Directors shall promptly reaffirm that grounds for a termination for Cause exist or reinstate Executive to his position hereunder. 

4.2. Death or Disability. Upon the death of Executive or written notice by the Company to Executive of termination of
the Executive for Disability (as defined below) given while the Executive remains Disabled. For purposes of this Section 4.2, “Disability” means (i) the Executive has been incapacitated by mental or physical injury or
illness so as to be prevented thereby from engaging in the performance of the Executive’s duties to the Company and (ii) such incapacity has continued for a period of one hundred twenty (120) consecutive days. 

4.3. By the Executive for Good Reason. At the election of the Executive, for Good Reason, provided that the Company
shall have thirty (30) days to cure in all material respects such Good Reason event(s) following the Company’s receipt of the Executive’s written notice of such Good Reason event(s). For the purposes of this Section 4.3,
“Good Reason” for termination shall mean (i) a reduction in the Executive’s Base Salary, (ii) any material diminution or other adverse change in the Executive’s authority, responsibilities or duties without the
prior written consent of the Executive, (iii) a material breach by the Company of this Agreement or any other material agreement between the Company and the Executive, (iv) the relocation, without the written consent of the Executive, of
the place of business at which the Executive principally performs Executive’s duties hereunder to a location that is greater than 50 miles from place of business at which the Executive principally performs Executive’s duties hereunder as
of the Effective Date, (v) the Executive’s removal from or failure to be elected to the Board of Directors or (vi) a Change of Control. Notwithstanding the foregoing, (A) the Executive will be deemed to have given consent to the
condition(s) described in this Section 4.3 if the Executive does not provide written notice to the Company of such Good Reason event(s) within ninety (90) days from first occurrence of such Good Reason event(s) and (B) to the extent
the Company has not cured such Good Reason event(s) during the thirty (30) day cure period, the Executive must terminate the Executive’s employment for Good Reason no later than one hundred eighty (180) days following the occurrence
of such Good Reason event(s) by providing the Company thirty (30) days prior written notice of termination, which may run concurrently with the Company’s cure period. 

  
 -5- 

 For purposes of this Agreement, “Change of Control” shall mean
(A) any acquisition of the Company by a Person (as defined below) not an Affiliate (as defined below) of the Company, by means of merger or other form of corporate reorganization in which the outstanding ownership interests of the Company are
exchanged for securities or other consideration issued, or caused to be issued, by the acquiring Person and in which the holders of the Company’s ownership interests hold less than fifty percent (50%) of the acquiring or surviving Person
(other than a mere reincorporation transaction), (B) the closing of the transfer from existing Company stockholders, in one transaction or a series of related transactions, to a Person or group of affiliated Persons, of the Company’s
securities if, after such closing, such Person or group of affiliated Persons would hold more than fifty percent (50%) of the outstanding voting securities of the Company, (C) a sale of all or substantially all of the assets of the Company
by a Person not an Affiliate of the Company or (D) individuals who, as of the Effective Date, constitute the Board of Directors (the “Incumbent Board”) cease for any reason to constitute at least a majority of the Board of
Directors; provided, however, that any individual becoming a director subsequent to the date hereof whose election, or nomination for election by the Company’s shareholders, was approved by a vote of at least of majority of the
directors then comprising the Incumbent Board shall be considered as though such individual was a member of the Incumbent Board, but excluding, for this purpose, any such individual whose initial assumption of the office occurs as a result of an
actual or threatened election contest with respect to the election or removal of directors of other actual or threatened solicitation of proxies or consents by or on behalf of a Person other than the Board of Directors; provided,
however, that a “Change of Control” shall not include an initial public offering of the Company’s stock or a mere recapitalization transaction. 

For purposes of this Agreement, an “Affiliate” means with respect to a specified Person, any Person that
directly or indirectly controls, is controlled by, or is under common control with, the specified Person (as used in this definition, the term “control” means the possession, directly or indirectly, of the power to direct or cause the
direction of the management and policies of a person or entity, whether through ownership of voting securities, by contract or otherwise). 

For purposes of this Agreement, a “Person” shall mean any individual, company, corporation, association,
partnership (general or limited), joint venture, trust, estate, limited liability company or other legal entity or organization. 

4.4. By the Company Not For Cause or By the Executive Not For Good Reason. At the election of the Company for reasons
other than Cause, or the election of the Executive for reasons other than Good Reason, upon not less than thirty (30) days’ prior written notice of termination. 

  
 -6- 

 5. Effect of Termination. 

5.1. Payments upon Termination. 

(a) In the event the Executive’s employment is terminated pursuant to Section 4.1, as a result of the death or
disability of the Executive pursuant to Section 4.2 or by the Executive pursuant to Section 4.4, the Company shall pay to the Executive (or his designated representative or estate) the “Accrued Benefits,” which shall mean:
(i) any earned but unpaid Base Salary pursuant to Section 3.1 through the last day of the Executive’s actual employment by the Company; (ii) any accrued but unused vacation time in accordance with the terms of applicable law;
(iii) any unreimbursed expenses incurred through the last day of the Executive’s actual employment by the Company and reimbursable under Section 3.5; (iv) all other payments, benefits or fringe benefits to which the Executive
shall be entitled under the terms of any applicable compensation arrangement or benefit, equity or fringe benefit plan or program or grant or this Agreement; but, for clarity, shall have no obligation to pay any amounts pursuant to Section 3.2;
and (v) in the case of death or termination due to Disability, a pro rata bonus paid sixty (60) days after termination based on the target Annual Bonus and the period of the year during which the Executive was employed. 

(b) In the event the Executive’s employment is terminated by the Executive pursuant to Section 4.3 or by the
Company pursuant to Section 4.4, in each case either one month prior to a Change of Control or after a Change of Control, then the Company shall pay to the Executive: (i) the Accrued Benefits; (ii) any unpaid Annual Bonus with respect
to the calendar year ending on or preceding the date of termination, which shall be payable at the time such bonuses would have been paid if the Executive was still employed with the Company and in accordance with Section 3.2(a); (iii) an
amount equal to three (3) times the sum of (A) the Base Salary pursuant to Section 3.1 as in effect on the date of termination plus (B) the highest of (x) Executive’s Annual Bonus paid for the year preceding the year of
termination, (y) Executive’s Annual Bonus paid at target for the year in which termination occurs and (z) Executive’s Base Salary in effect at the time of termination, which amount shall be paid in a lump sum on the sixtieth (60th) day following the date of termination; and (iv) reimbursement for COBRA continuation medical benefits for the Executive (and the Executive’s eligible dependents) for a period of
eighteen (18) months following the date of termination. The payments under subpart (iv) shall begin on the sixtieth (60th) day after the date of termination and shall include any
amounts due prior to such date. For the avoidance of doubt, unless otherwise elected by the Board of Directors, in its sole discretion and to the extent permitted under Section 409A of the Internal Revenue Code of 1986, as amended (the
“Code”), to make payments sooner, any payments made pursuant to this Section 5.1(b) shall be subject to the Company’s standard payroll schedule. 

(c) In the event the Executive’s employment is terminated by the Executive pursuant to Section 4.3 or by the
Company pursuant to Section 4.4, in each case outside of the time frame referenced in Section 5.1(b) above, then the Company shall pay to the Executive: (i) the Accrued Benefits; (ii) any unpaid Annual Bonus with respect to the
calendar year ending on or preceding the date of termination, which shall be payable at the time such bonuses would have been paid if the Executive were still employed with the Company and in accordance with Section 3.2(a); (iii) an amount
equal to two (2) times the sum of (A) the Base Salary pursuant to Section 3.1 as in effect on the date of termination plus (B) the highest of (x) Executive’s Annual Bonus paid for the year preceding the year of
termination, (y) Executive’s Annual Bonus paid at target for the year in which termination occurs and (z) Executive’s Base Salary in effect at the time of termination, which amount shall be paid in a lump sum on the sixtieth (60th) day following the 

  
 -7- 

 
date of termination; and (iv) reimbursement for COBRA continuation medical benefits for the Executive (and the Executive’s eligible dependents) for a period of eighteen (18) months
following the date of termination. The payments under subpart (iv) shall begin on the sixtieth (60th) day after the date of termination and shall include any amounts due prior to such
date. For the avoidance of doubt, unless otherwise elected by the Board of Directors, in its sole discretion and to the extent permitted under Section 409A of the Code, to make payments sooner, any payments made pursuant to this
Section 5.1(c) shall be subject to the Company’s standard payroll schedule. 
 (d) The payments to be made or
benefits to be provided to the Executive under paragraphs (b) or (c) above other than Accrued Benefits: (i) shall be contingent upon the execution (and non-revocation) within sixty (60) days following termination of employment by
the Executive of a general release of the Company, its affiliates, stockholders, directors, officers, employees and agents from all claims (other than claims for the payments to be made and benefits to be provided), together with a mutual agreement
to not make any disparaging comments, statements or communications about the Executive, the Company, its affiliates, stockholders, directors, officers, employees or agents, or its management or business practices for three (3) years following
termination of the Executive’s employment, all in substantially the form annexed hereto as Exhibit A and (ii) shall constitute the sole remedy of the Executive in the event of a termination of the Executive’s employment in the
circumstances set forth in Section 5.1(b) or 5.1(c). 
 5.2 Treatment of Equity Upon Termination or Change of
Control 
 (a) It is understood and agreed that all equity awards granted to the Executive from and after the Effective
Date shall be subject to the following vesting acceleration provisions: (i) upon the consummation of a Change of Control (including a termination without Cause or resignation for Good Reason in accordance with Sections 4.3 or 5.1(b) in
connection with a Change of Control), all of the Executive’s then-outstanding equity awards shall become immediately fully vested and, to the extent stock options or stock appreciation rights, exercisable, and (ii) in the event the
Executive is terminated by the Company without Cause or the Executive Resigns for Good Reason (and (i) above does not apply), (A) the Executive shall receive twenty-four (24) months of vesting acceleration on all of the
Executive’s then-outstanding time-based equity awards and (B) with respect to the Executive’s then-outstanding performance-based equity awards, the Executive shall be deemed to have satisfied the service-based component of the portion
of such awards that would have vested based on service within twenty-four (24) months of the date of such termination and the Executive shall be eligible to vest with respect to the performance-based component of such awards if the performance
criteria are satisfied within twenty-four (24) months of the Executive’s termination of employment. All options or stock appreciation rights that become vested in accordance with this Section 3.3(b) shall remain outstanding and
exercisable (to the extent not already exercised) for a period of three (3) years, measured from the date of the consummation of the Change of Control, or if later, the date of the Executive’s termination of employment. 

  
 -8- 

 5.3 Section 409A. 

(a) Notwithstanding anything to the contrary in this Agreement, no severance pay or benefits to be paid or provided to the
Executive, if any, pursuant to this Agreement that, when considered together with any other severance payments or separation benefits, are considered deferred compensation under Code Section 409A, and the final regulations and any guidance
promulgated thereunder (collectively, the “Deferred Payments”) will be paid or otherwise provided until the Executive has a “separation from service” within the meaning of Code Section 409A. 

(b) Notwithstanding anything to the contrary in this Agreement, if the Executive is a “specified employee” within
the meaning of Code Section 409A at the time of the Executive’s termination (other than due to death), then the Deferred Payments that are payable within the first six months following the Executive’s separation from service, will
become payable on the first payroll date that occurs on or after the date six months and one day following the date of the Executive’s separation from service. Notwithstanding anything herein to the contrary, if the Executive dies following the
Employee’s separation from service, but prior to the six-month anniversary of the separation from service, then any payments delayed in accordance with this paragraph will be payable in a lump sum (with interest as provided for below) as soon
as administratively practicable after the date of the Executive’s death. Each payment and benefit payable under this Agreement is intended to constitute a separate payment for purposes of Section 1.409A-2(b)(2) of the Treasury Regulations.
Any delayed payments shall be credited with interest at a rate equal to the short term applicable federal rate (“AFR”) then in effect until paid. 

(c) Any amount paid under this Agreement that satisfies the requirements of the “short-term deferral” rule set
forth in Section 1.409A-1(b)(4) of the Treasury Regulations will not constitute Deferred Payments. If under this Agreement, an amount is to be paid in two or more installments, for purposes of Code Section 409A, each installment shall be
treated as a separate payment. 
 (d) This Agreement is intended to be exempt from the requirements of Code
Section 409A or compliant therewith so that none of the payments and benefits to be provided hereunder will be subject to the additional tax imposed under Section 409A, and any ambiguities herein will be interpreted accordingly. The
Company and the Executive agree to work together in good faith to consider amendments to this Agreement and to take such reasonable actions which are necessary, appropriate or desirable to avoid imposition of any additional tax or income recognition
prior to actual payment to the Executive under Section 409A. 
 6. Covenant Not to Compete. Except with the
prior written consent of the Board of Directors, the Executive will not, during the term of this Agreement, engage in competition with the Company or any of its Affiliates, either directly or indirectly, in any manner or capacity, as advisor,
principal, agent, affiliate, promoter, partner, officer, director, employee, stockholder, owner, co-owner, consultant or member of any association or otherwise, in any phase of the business of developing, manufacturing and marketing of products or
services which are in the same field of use or which otherwise compete with the products or services or proposed products or services of the Company or any of its Affiliates. 

  
 -9- 

 7. Other Agreements. The Executive represents that the Executive’s
performance of all the terms of this Agreement and the performance of the Executive’s duties as an employee of the Company do not and will not breach any agreement with any prior employer or other party to which the Executive is a party
(including without limitation any nondisclosure or non- competition agreement), or violate or contravene any judgment, administrative order or other legal prohibition specifically naming the Executive. The Executive agrees that if the Executive,
during the Employment Period, becomes subject to any such agreement or prohibition, the Executive shall immediately notify the Company. 

8. Confidential Information. 

8.1. The Executive understands and agrees that the information obtained and the various projects undertaken by the Executive
in the performance of his duties as an employee of the Company may involve confidential, proprietary, and trade-secret information of the Company or the Company’s customers. The Executive further understands and agrees that the Executive will
have access to knowledge or information of a confidential, proprietary, or trade secret nature concerning the Company or the Company’s customers, and that the Executive shall receive such information in confidence, solely for the benefit of the
Company. The Executive agrees that the Executive shall not disclose any such information to anyone not specifically authorized by the Company to receive it, and shall not use the information for the Executive’s benefit or the benefit of any
person or entity, other than the Company, at any time during or after the term of this Agreement, unless the Executive is required to pursuant to law, regulation or a subpoena issued by a court of competent jurisdiction; provided,
however, that Executive must give the Company notice within five (5) business days after receiving notice of such a request to produce Confidential Information for the purpose of allowing the Company to contest such a request. The
Executive shall not be required to contest such a request. 
 8.2. For the purposes of this Agreement,
“Confidential Information” means proprietary information or material disclosed to Executive or known to Executive as a consequence of or through performance of services as an employee of the Company, whether or not related to his
duties and responsibilities as an employee, whether or not such proprietary information or materials is patentable, belonging to the Company (or to any corporation, firm, or partnership directly or indirectly controlled by or controlling the Company
or in which any of the aforesaid have more than 20% ownership interest) including, but not limited to, trade secrets (including, for example and without limitation, trade secrets as defined by substantive California law governing “trade
secrets,” processes, formulas, data, know-how, improvements, inventions, computer software, programs, circuit designs, masks, test results, techniques, marketing and product plans and strategies, and information concerning customers or vendors,
formulations, techniques, methodology, equipment, data, reports, know-how, sources of supply, products, processes, systems, machinery, materials, research activities and plans, cost of production, contract forms, prices, volume of sales, promotional
methods, lists of names or classes of customers, inventions, disclosures, patents, patent applications, patent positioning, customer and buyer contacts and lists, supplier’s prices or rebates, pricing practices, technical data, personnel and
salary information, names and addresses, and information relating to financial arrangements, contracts, operating practices or plans of the Company, consultants and business plans, including any negative technical or business developments, which are
communicated to, learned of, developed or otherwise acquired by the party receiving such information or materials during or 

  
 -10- 

 
in the course of the agreement, including information concerning the existence, scope or activities of any research and development project of the Company. Information shall be considered, for
purposes of this Agreement, to be Confidential Information if not known by the trade generally, even though such information has been disclosed to one or more third parties pursuant to distribution agreements, joint research agreements, or other
agreements entered into by the Company or any of its affiliates. For purposes of this Agreement, information shall not be considered Confidential Information to the extent that such information is or becomes, through no fault or action of Executive,
part of the public domain, such information is independently known to Executive, or such information is lawfully furnished to Executive by a third party without restriction on disclosure. 

8.3. Upon the termination of the Executive’s employment, the Executive shall, at the Company’s option, surrender to
the Company, destroy or maintain in confidentiality in accordance with the standard set forth in this Agreement, all property provided to the Executive by the Company for use in relation to the Executive’s employment, and, in addition, the
Executive shall surrender to the Company any and all sales materials, lists of customers and prospective customers, price lists, files, patent applications or disclosures with respect thereto, diagrams, records, models, or other materials and
information of or pertaining to the Company or its customers or prospective customers or the products, business, and operations of the Company; provided, however, the Executive shall be permitted to retain his personal address book. 

9. Miscellaneous. 

9.1. Notices. Any notices delivered under this Agreement shall be deemed duly delivered four (4) business days
after it is sent by registered or certified mail, return receipt requested, postage prepaid, or one business day after it is sent for next-business day delivery via a reputable nationwide overnight courier service, in each case to the address of the
recipient set forth in the introductory paragraph of this Agreement. Either party may change the address to which notices are to be delivered by giving notice of such change to the other party in the manner set forth in this Section 9.1. 

9.2. Pronouns. Whenever the context may require, any pronouns used in this Agreement shall include the corresponding
masculine, feminine or neuter forms, and the singular forms of nouns and pronouns shall include the plural, and vice versa. 

9.3. Entire Agreement. This Agreement constitutes the entire agreement between the parties and supersedes all prior
agreements and understandings, whether written or oral, relating to the subject matter of this Agreement. 
 9.4.
Amendment. This Agreement may be amended or modified only by a written instrument executed by both the Company and the Executive. 

9.5. Governing Law. This Agreement shall be governed by and construed in accordance with the laws of the State of
California (without reference to the conflicts of laws provisions of the State of California). 
 9.6. Resolution of
Disputes. Any dispute, difference or controversy arising under this Agreement shall be settled by arbitration. Any arbitration pursuant to this Section shall 

  
 -11- 

 
be held before a single neutral arbitrator selected from the roles of the American Arbitration Association pursuant to the Commercial Arbitration Rules. The arbitrator shall interpret and
construe this Agreement in accordance with, and shall be bound by the laws of the State of California. Any arbitration shall take place in San Diego, California or at such other location as the parties may agree upon, according to the American
Arbitration Association’s Commercial Arbitration Rules now in force and hereafter adopted. The arbitrator shall make any award in accordance with and based upon all the provisions of this Agreement and judgment upon any award rendered by the
arbitrator shall be entered in any court having jurisdiction thereof. The fees and disbursements of such arbitrator shall be borne equally by the parties, with each party bearing its own expenses for counsel and other out-of-pocket costs.
Notwithstanding the preceding sentence, if the arbitrator determines that Executive is the prevailing party in the dispute, then the Company shall reimburse Executive for his reasonable legal or other fees and expenses incurred in such arbitration
subject to and within ten (10) days after Executive’s request for reimbursement accompanied by evidence that the fees and expenses were incurred. Any reimbursement hereunder shall be paid to Executive promptly and in no event later than
the end of the year next following the date the expense was incurred. 
 9.7. Successors and Assigns. This Agreement
shall be binding upon and inure to the benefit of both parties and their respective successors and assigns, including any corporation with which, or into which, the Company may be merged or which may succeed to the Company’s assets or business,
provided, however, that the obligations of the Executive are personal and shall not be assigned by the Executive. The Company may only assign this Agreement to any successor to all or substantially all of the business and/or assets of
the Company, provided that the Company shall secure such successor’s written agreement to expressly assume and agree to perform this Agreement in the same manner and to the same extent that the Company would be required to perform it if
no such succession had taken place. As used in this Agreement, “Company” shall mean the Company and any successor to its business and/or assets, which assumes and agrees to perform the duties and obligations of the Company under
this Agreement by operation of law or otherwise. 
 9.8. Waivers. No delay or omission by the Company or the
Executive in exercising any right under this Agreement shall operate as a waiver of that or any other right. A waiver or consent given by the Company or the Executive on any one occasion shall be effective only in that instance and shall not be
construed as a bar or waiver of any right on any other occasion. 
 9.9. No Mitigation; No Offset. In no event shall
the Executive be obligated to seek other employment or take any other action by way of mitigation of the amounts payable to the Executive under any of the provisions of this Agreement, nor shall the amount of any payment hereunder be reduced by any
compensation earned by the Executive as a result of employment by a subsequent employer. 
 9.10. Captions. The
captions of the sections of this Agreement are for convenience of reference only and in no way define, limit or affect the scope or substance of any section of this Agreement. 

  
 -12- 

 9.11. Severability. In case any provision of this Agreement shall be
invalid, illegal or otherwise unenforceable, the validity, legality and enforceability of the remaining provisions shall in no way be affected or impaired thereby. 

9.12. Execution; Counterparts. This Agreement may be executed in several counterparts, each of which shall be deemed
to be an original but all of which together will constitute one and the same instrument. This Agreement may be executed and delivered by facsimile, email/pdf format or other electronic means and each party may fully rely upon such execution and
delivery. 
 9.13. Survival. The provisions of Sections 3.7 and 5 through 10 shall survive the termination of this
Agreement. 
 9.14. 280G. 

(a) If any payment or benefit (including payments and benefits pursuant to this Agreement) that Executive would receive from
the Company or otherwise in connection with a Change of Control (“Transaction Payment”) would (i) constitute a “parachute payment” within the meaning of Section 280G of the Code, and (ii) but for this
Section 9.14, be subject to the excise tax imposed by Section 4999 of the Code (the “Excise Tax”), then the Company shall cause to be determined, before any amounts of the Transaction Payment are paid to Executive, which
of the following two alternative forms of payment would result in Executive’s receipt, on an after-tax basis, of the greater amount of the Transaction Payment notwithstanding that all or some portion of the Transaction Payment may be subject to
the Excise Tax: (1) payment in full of the entire amount of the Transaction Payment (a “Full Payment”), or (2) payment of only a part of the Transaction Payment so that Executive receives the largest payment possible
without the imposition of the Excise Tax (a “Reduced Payment”). 
 For purposes of determining whether to
make a Full Payment or a Reduced Payment, the Company shall cause to be taken into account all applicable federal, state and local income and employment taxes and the Excise Tax (all computed at the highest applicable marginal rate, net of the
maximum reduction in federal income taxes which could be obtained from a deduction of such state and local taxes). If a Reduced Payment is made, (x) Executive shall have no rights to any additional payments and/or benefits constituting the
Transaction Payment, and (y) reduction in payments and/or benefits shall occur in the manner that results in the greatest economic benefit to Executive as determined in this paragraph. If more than one method of reduction will result in the
same economic benefit, the portions of the Payment shall be reduced pro rata. 
 (b) The independent registered public
accounting firm engaged by the Company as of the day prior to the effective date of the Change of Control shall make all determinations required to be made under this Section 9.14. If the independent registered public accounting firm so engaged
by the Company is serving as accountant or auditor for the individual, entity or group effecting the Change of Control, the Company shall appoint a nationally recognized independent registered public accounting firm that is reasonably acceptable to
Executive (and such acceptance shall not be unreasonably withheld) to make the determinations required hereunder. The Company shall bear all reasonable expenses with respect 

  
 -13- 

 
to the determinations by such independent registered public accounting firm required to be made hereunder. The independent registered public accounting firm engaged to make the determinations
hereunder shall provide its calculations, together with detailed supporting documentation, to the Company and Executive within fifteen (15) calendar days after the date on which Executive’s right to a Transaction Payment is triggered or
such other time as reasonably requested by the Company or Executive. If the independent registered public accounting firm determines that no Excise Tax is payable with respect to the Transaction Payment, either before or after the application of the
Reduced Amount, it shall furnish the Company and Executive with detailed supporting calculations of its determinations that no Excise Tax will be imposed with respect to such Transaction Payment. Any good faith determinations of the accounting firm
made hereunder shall be final, binding and conclusive upon the Company and Executive. 
 (c) Notwithstanding the foregoing,
to the extent that the Company of Holdings does not have any readily tradable public stock, and in the event that it shall be determined that any right to receive any Transaction Payment would not be deductible, in whole or part when aggregated with
any other right, payment or benefit to or for the Executive under all other agreements or benefit plans of the Company, by the Company or the person making such payment or distribution or providing such right or benefit as a result of
Section 280G of Code, the Company shall use its commercially reasonable best efforts to prepare and deliver to its stockholders the disclosure required by Section 280G(b)(5)(B) of the Code with respect to any Transaction Payment to obtain
the approval of the Company’s stockholders in accordance with Section 280G(b)(5)(B) of the Code and the regulation codified at 26 C.F.R. §1.280G-1, and Executive shall us his reasonable best efforts to cooperate in connection with
such procedure (including, if required, executing a waiver of any Transaction Payment to which he might otherwise be entitled that may be submitted for approval to such stockholders). 

  
 -14- 

 [THIS PAGE INTENTIONALY LEFT BLANK] 

  
 -15- 

 [SIGNATURE PAGE TO EXECUTIVE EMPLOYMENT AGREEMENT EFFECTIVE 

JANUARY 1, 2015] 

IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the day and year set forth above. 

 

			
	 CONKWEST, INC.

	
	 /s/ Steve Gorlin

	 By:
		 Steve Gorlin

	 Its:
		 Vice Chairman of the Board

	
	 EXECUTIVE

	
	 /s/ Barry J. Simon

	 Name:
		 Barry J. Simon, M.D.

  

  
 -16- 

 Exhibit A 

FORM OF GENERAL RELEASE 

Barry J. Simon, M.D. (“Employee”), in consideration for receiving the severance benefits described in [Section 5.1(b)/Section
5.1(c)] of that certain Executive Employment Agreement (the “Employment Agreement”) between Employee and Conkwest, Inc. (the “Employer”), does hereby fully release the Employer, including all of its past, present
and future directors, members, officers, stockholders, employees, agents, affiliates and representatives, from any and all claims of every kind and nature whatsoever, known or unknown, either at law or in equity, arising out of or related to his
employment with, service to, or engagement with the Employer and/or termination of employment or pursuant to any federal, state or local laws, regulations, executive orders or other requirements, including but not limited to alleged violations of
the California Labor Code, the California Fair Employment and Housing Act, the Age Discrimination in Employment Act (“ADEA”), any claims arising out of any employment agreement entered into by Employee and Employer and any claims of
discrimination based upon race, color, sex, age, religion, national or ethnic origin, sexual orientation, disability, handicap, status as a Vietnam Era Veteran, or any other protected classification; provided, however, that nothing in
this release shall operate to limit or negate Employee’s rights, if any, (i) to indemnification (and advancement of legal fees) by the Company for any acts or omissions taken by Employee in good faith as an officer or director of the
Company or as a fiduciary of any benefit plan of the Company; (ii) to directors’ and officers’ liability insurance; (iii) to any vested equity and any rights set forth in agreements related thereto; or (iv) to
post-termination compensation and benefits to which Employee is entitled under his employment agreement with Employer. 
 Employee
represents that he understands the various claims he could have asserted under the American with Disabilities Act, Title VII of the Civil Rights Act of 1964, the Age Discrimination In Employment Act, and other such similar laws; that he has read
this Release carefully and understands all of its provisions; that he understands that he has the right to and is advised to consult an attorney concerning this Release and in particular the waiver of rights he might have under these laws; that to
the extent, if any, that he desired, he has availed himself of this right; that the consideration received by him is above and beyond the payments or benefits otherwise owed to him under the terms of him employment with the Employer or required by
law; that he has, pursuant to the Older Workers Benefit Protection Act, been provided at least twenty-one (21) days to consider whether to sign this Release; and that he enters this Release and waives any claims knowingly and willingly. 

In addition to the foregoing, Employee hereby agrees he is waiving all rights under Paragraph 1542 of the California Civil Code (or any
analogous law of any other state), which reads as follows: 
 “A GENERAL RELEASE DOES NOT EXTEND TO CLAIMS WHICH THE CREDITOR DOES NOT
KNOW OR SUSPECT TO EXIST IN HIS OR HER FAVOR AT THE TIME OF EXECUTING THE RELEASE, WHICH IF KNOWN BY HIM OR HER MUST HAVE MATERIALLY AFFECTED HIS OR HER SETTLEMENT WITH THE DEBTOR.” 

  
 -17- 

 This Release will not affect the rights and responsibilities of the U.S. Equal Employment
Opportunity Commission (“EEOC”) to enforce the ADEA and other laws, but Employee understands that he is knowingly and voluntarily waiving all rights or claims arising prior to his execution of the Release to receive any payment,
benefit or remedial relief as a consequence of any charge filed with the EEOC and/or of any litigation concerning any facts alleged in any such charge. 

Employee acknowledges and agrees that, but for providing this general release, Employee would not be receiving the benefits described in
[Section 5.1(b)/Section 5.1(c)] of the Employment Agreement. 
 Employee agrees that for three (3) years following his termination from
the Employer, he will not make any statements that are disparaging or adverse to the Employer, its affiliates, stockholders holding more than 5% of the Employer’s outstanding capital stock, directors, officers, or employees, or its management
or business practices. Employer agrees that for three (3) years following Employee’s termination, its directors and executive officers will not to make any statements that are disparaging or adverse to the Employee, including any statement
that disparages any skills, work performance, capabilities or other aspect of Employee’s service as an employee of the Employer; provided, that these provisions shall not prohibit any party (A) from disclosing that Employee is no longer
employed by the Employer, (B) from responding truthfully to any governmental investigation, legal process or related inquiry, (C) from making reasonable competitive statements in the course of promoting a competing business, or
(D) making a good faith rebuttal of another person’s untrue or misleading statement. 
 This Release will become effective seven
(7) days after it is signed. Employee may revoke this Release within seven (7) days after it is signed, and it will not become effective or enforceable until this seven (7) day revocation period has expired. After the revocation
period has expired, this Release will be forever binding on the Employee. The Employee acknowledges that he may hereafter discover facts not now known to him relating to his hire, employment or termination of employment, and agrees that this Release
will remain in effect notwithstanding any such discovery of any such facts. The Employee will not bring any proceeding to challenge the validity of this Release. 

  
 -18- 

 IN WITNESS WHEREOF, Barry J. Simon has caused this instrument of GENERAL RELEASE
to be executed and sealed on this              day of
                        , 20    . 

 

	
	  

	 Barry J. Simon

 Signed and sealed in the presence of: 
  

	
	  

	 Notary Public

	 My Commission expires:

  
 -19-EX-10.7

 CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH PORTION, WHICH HAS
BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***], HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
 Exhibit
10.7 
 AGREEMENT 

This Agreement (this “Agreement”), dated and effective as of June 9, 2015 (“Effective Date”), is by and
between Brink Biologics, Inc. (dba Bank Biologics) (“BANK”), a Delaware corporation with offices at 2533 South Coast Highway 101, Suite 210, Cardiff-By-The-Sea, CA 92007-2133, and CONKWEST INCORPORATED
(“CONKWEST”), a Delaware corporation with offices at 2533 South Coast Highway 101, Suite 210, Cardiff-By-The-Sea, CA 92007-2133. 

PREAMBLE 
 A. WHEREAS,
CONKWEST is an innovative life sciences company that owns and/or controls the rights in certain CONKWEST Existing Rights (as defined herein) and has the right to grant licenses thereto; 

B. WHEREAS, BANK is an innovative life sciences company specializing in the field of in vitro and in vivo testing and diagnostic
products and services (the “Field”); and 
 C. WHEREAS, BANK desires to obtain rights to use certain of the CONKWEST Existing
Rights in the Field, and CONKWEST desires to grant such certain rights to BANK, upon the terms and conditions hereinafter set forth. 
 NOW
THEREFORE, in consideration of the above premises and the mutual covenants contained herein, BANK and CONKWEST, intending to be legally bound, agree as follows: 

1. Definitions. For the purposes hereof, the following words and phrases have the following meanings: 

“AAA” has the meaning ascribed to it in Section 24. 

“BANK BIOLOGICS Mark” means the trademark and/or service mark applied for in US Trademark Application No. 86/347,873,
such trade mark application and any registration resulting therefrom, any foreign or Madrid counterparts, any renewals thereof, and any goodwill associated therewith. 

  
 -1- 

 “BANK Cell Bank(s)” means any GLP, cGMP, and/or GMP-certified BANK Cell Line(s).

 “BANK Cell Line(s)” means any modification or derivative of or improvement to a CONKWEST Cell Line resulting from a BANK
Modification. 
 “BANK Confidential Information” means all Confidential Information relating to the BANK Cell Lines to the
extent owned and controlled by CONKWEST. 
 “BANK Intellectual Property” means BANK Confidential Information and BANK
Patents pertaining to the BANK Modifications. 
 “BANK Modifications” has the meaning ascribed to it in Section 2 and
includes any and all BANK Intellectual Property, BANK Cell Line(s) and BANK Cell Bank(s) relating thereto. 
 “BANK Option”
has the meaning ascribed to it in Section 2. 
 “BANK Patents” means any and all patents and patent applications to
the extent owned and controlled by CONKWEST relating to the BANK Modifications, and any provisional patent applications, non-provisional applications, divisionals, continuations, continuation-in-part applications, continued prosecution, patents
granted on such applications, revalidations, reissues, renewals, substitutions, supplementary protection certificates and the like, and patents of addition, reexaminations, extensions; and all foreign counterparts thereof. 

“BANK Rights” means the BANK Modifications and BANK Intellectual Property. 

“Biological Material” means a culture of any of the CONKWEST Cell Lines or CONKWEST Cell Banks that is provided to BANK by
CONKWEST pursuant to this Agreement and all Progeny thereof. 
 “Claims” has the meaning ascribed to it in Section 9.

  
 -2- 

 “Commercial Product” means a Licensed Product that has been granted marketing
and Regulatory Approval. 
 “Confidential Information” means all technical and other information, data, methods, pricing
information, inventions (whether patentable or not and whether or not reduced to practice), Know-How, and other similar proprietary trade secret rights arising under law anywhere in the world. 

“CONKWEST Cell Banks” means the CONKWEST WT Master Cell Bank and the CONKWEST WT Working Cell Bank. 

“CONKWEST Cell Lines” means the CONKWEST CI Cell Line, the CONKWEST ER Cell Line, the CONKWEST MI Cell Line, and the CONKWEST
WT Cell Line. 
 “CONKWEST CI Cell Line” means the proprietary natural killer cell line transfected with the pCEP4-LTRhIL-2
vector to express endogenous interleukin-2 and that is owned and controlled by CONKWEST as of the Effective Date. For clarity, CONKWEST CI Cell Line does not include any modifications, derivatives, or improvements thereof made by or under the
authority of CONKWEST or any Third Parties after the Effective Date. 
 “CONKWEST Confidential Information” means all
Confidential Information relating to the CONKWEST Cell Lines that is owned and controlled by CONKWEST. For clarity, CONKWEST Confidential Information expressly includes, but is not limited to, CONKWEST Know-How and CONKWEST Report. 

“CONKWEST ER Cell Line” means the proprietary natural killer cell line transfected with the endoplasmic reticulum (ER) gene
encoding the protein known as the KDEL motif and that is owned and controlled by CONKWEST as of the Effective Date. For clarity, CONKWEST ER Cell Line does not include any modifications, derivatives, or improvements thereof made by or under the
authority of CONKWEST or any Third Parties after the Effective Date. 
 “CONKWEST Existing Rights” means CONKWEST Cell
Lines, CONKWEST Intellectual Property, and CONKWEST Cell Banks. 

  
 -3- 

 “CONKWEST Intellectual Property” means all CONKWEST Confidential Information and
CONKWEST Patents pertaining to the CONKWEST Cell Lines that are owned and controlled by CONKWEST as of the Effective Date, the CONKWEST Marks, and the Domain Name. 

“CONKWEST Know-How” means all Know-How pertaining to the CONKWEST Cell Lines that is owned and controlled by CONKWEST as of
the Effective Date, including that which is described on Schedule B hereto. CONKWEST Know-How does not include CONKWEST Patents. 

“CONKWEST Marks” means those marks listed on Schedule C hereto, which may be updated from time to time, owned and controlled
by CONKWEST and any and all registrations and applications therefore in the United States and around the world. For clarity, the CONKWEST Marks include the BANK BIOLOGICS Mark, unless and until BANK acquires such trademark pursuant to the BANK
Option under Section 2(d) below. 
 “CONKWEST MI Cell Line” means the proprietary natural killer cell line transfected
with the MFG-hIL-2 vector to express endogenous interleukin-2, and that is owned and controlled by CONKWEST as of the Effective Date. For clarity, CONKWEST MI Cell Line does not include any modifications, derivatives, or improvements thereof made by
or under the authority of CONKWEST or any Third Parties after the Effective Date. 
 “CONKWEST Patents” means the patents
and patent applications owned and controlled by CONKWEST that are listed on Schedule A hereto, which may be updated from time to time, and any provisional patent applications, non-provisional applications, divisionals, continuations,
continuation-in-part applications, continued prosecution, patents granted on such applications, revalidations, reissues, renewals, substitutions, supplementary protection certificates and the like, and patents of addition, reexaminations,
extensions; and all foreign counterparts thereof. 
 “CONKWEST Report” has the meaning ascribed to it in Section 2.

 “CONKWEST WT Cell Line” means the proprietary natural killer cell line known as the NK-92 wild type cell line, and that
is owned and controlled by CONKWEST as of the Effective Date. For clarity, the CONKWEST WT Cell Line does not include the CD16 

  
 -4- 

 
expressing NK-92 cell line or any other modifications, derivatives, or improvements of the CONKWEST WT Cell Line made by or under the authority of CONKWEST or any Third Parties after the
Effective Date. 
 “CONKWEST WT Master Cell Bank” means the GMP-certified CONKWEST WT Cell Line. CONKWEST Master Cell Bank
does not include any modifications, derivatives, or improvements to the CONKWEST WT Cell Line made by or under the authority of CONKWEST or any Third Parties after the Effective Date. 

“CONKWEST WT Working Cell Bank” means the GLP and cGMP unmodified CONKWEST WT Cell Line. CONKWEST WT Working Cell Bank does
not include any modifications, derivatives, or improvements to the CONKWEST WT Cell Line made by or under the authority of CONKWEST or any Third Parties after the Effective Date. 

“Domain Name” has the meaning ascribed to it in Section 2. 

“Excluded Claim” has the meaning ascribed to it in Section 24. 

“FCCC Rights” has the meaning ascribed to it in Section 2. For clarity, any patents included in the FCCC Rights
controlled by CONKWEST are listed on Schedule D hereto, which may be updated from time to time, and any provisional patent applications, non-provisional applications, divisionals, continuations, continuation-in-part applications, continued
prosecution, patents granted on such applications, revalidations, reissues, renewals, substitutions, supplementary protection certificates and the like, and patents of addition, reexaminations, extensions; and all foreign counterparts thereof. 

“Field” has the meaning ascribed to it in the Preamble. 

“Force Majeure” means in relation to either Party, any event or circumstance (other than lack of funds) which is beyond the
reasonable control of that Party which event or circumstance that Party could not reasonably be expected to have taken into account at the date of this Agreement and which results in or causes the failure of that Party to perform any or all of its
obligations under this Agreement including, but not limited to, act of God, lightning, fire, storm, flood, earthquake, accumulation of snow or ice, lack of water arising from weather or 

  
 -5- 

 
environmental problems, strike, lockout or other industrial or student disturbance, act of the public enemy, war declared or undeclared, threat of war, terrorist act, blockade, revolution, riot,
insurrection, civil commotion, public demonstration, sabotage, act of vandalism, prevention from or hindrance in obtaining in any way materials, energy or other supplies, explosion, fault or failure of plant or machinery (which could not have been
prevented by good industry practice), or legal requirement governing either Party or acts, omissions or delays in acting by any governmental authority. 

“Gross Revenue” means gross receipts actually received by BANK or its sublicensees from the Sale of a Commercial Product,
Licensed Product, or Licensed Service, as the case may be. 
 “Indemnitees” means agents, directors, officers and employees
of a Party entitled to indemnification hereunder and their respective successors, assigns, administrators, executors and/or heirs. 

“Indemnitor” has the meaning ascribed to it in Section 9. 

“Innocent Party” has the meaning ascribed to it in Section 12. 

“Licensed Product” or “Licensed Service” means a product or service, as the case may be, which
(i) utilizes, utilized, or otherwise relies upon or relied upon, any or all of the CONKWEST Cell Lines and/or the CONKWEST Cell Banks or (ii) would, but for the licenses granted pursuant to Section 2(a)(ii) or Section 2(c)
hereto, infringe a Valid Claim.  
 “Non-Performing Party” has the meaning ascribed to it in Section 12. 

“Party” or “Parties” means CONKWEST, BANK, or both, depending on the context. 

“Person” or “person” means any corporation, partnership, limited liability company, joint venture, other
entity, or natural person. 
 “Progeny” means unmodified descendants from the Biological Material, such as virus from
virus, cell from cell or organism from organism. 

  
 -6- 

 “Quality Standards” means the quality levels which CONKWEST maintains in
connection with the CONKWEST Marks. 
 “Regulatory Approval” means, with respect to a state, nation or multinational
jurisdiction, (i) any approvals, licenses, registrations or authorizations necessary for the manufacture (where relevant), marketing and sale of a Licensed Product or Licensed Service in such state, nation or jurisdiction, and (ii) where
relevant, pricing approvals necessary to obtain reimbursement from a Government Authority. 
 “Results” has the meaning
ascribed to it in Section 6. 
 “Royalty” has the meaning ascribed to it in Section 5. 

“Sale” means any transaction that transfers to an arm’s-length Third Party purchaser, for value, title and right of
physical possession to a Commercial Product, a Licensed Product, or a Licensed Service. Correspondingly, “Sell” means to make or cause to be made a Sale and “Sold” to have made or caused to be made a Sale. 

“Sublicensing Revenue” means any amounts received by BANK from a non-Affiliated Third Party in consideration
for the grant by BANK to such Third Party of (i) a sublicense under the CONKWEST Existing Rights and/or, if permitted, the FCCC Rights or (ii) the right to develop and/or commercialize any Licensed Product(s), Licensed Service(s) and/or
Commercial Product(s), including any upfront payments, annual fees or maintenance payments, milestone payments or the like, but excluding: (a) amounts paid by such a Third Party as bona fide reimbursement for research, development and/or other
costs that BANK is obligated to incur in the performance of activities in accordance with such agreement, (b) bona fide loans, (c) amounts paid for supplies of product or other tangible materials; and (d) royalties paid based on sales
of Licensed Products, Licensed Services and/or Commercial Products; provided that BANK pays to CONKWEST any Royalties due to CONKWEST with respect thereto under Section 5(a)(i) or (5(a)(ii) below, as applicable. 

“Tax” means all charges, duties, fees, levies or other assessments imposed by any tax authority, including but not limited to
income, excise, property, sales, use, value added, profit, license, payroll, employment, net worth, capital gains, transfer, stamp, social security, environmental, occupation and franchise taxes, and includes any interest, penalties and additions on
these payments. 

  
 -7- 

 “Term” has the meaning ascribed to it in Section 11. 

“Third Party” means any Person other than CONKWEST or BANK. 

“Transfer” has the meaning ascribed to it in Section 2. 

“Valid Claim” means a bona fide claim of any issued or pending CONKWEST Patent or patent rights included in the FCCC Rights
whose enforceability has not been affected by one or more of any of the following: (i) irretrievable lapse, expiration, revocation, cancellation or abandonment, and/or (ii) holding of unenforceability or invalidity by a decision of a court
or other appropriate body of competent jurisdiction, unappealable or unappealed within the time allowed for appeal, and/or (iii) disclaimer or admission of invalidity or unenforceability through reissue or re-examination or opposition, nullity
action or invalidation suit response or otherwise. 
 “ZelleRx-FCCC License” has the meaning ascribed to it in
Section 2. 
 2. Grant of Rights. 

(a) Licenses to CONKWEST Rights. Subject to the terms and conditions of this Agreement, CONKWEST hereby grants to BANK, the following
rights and licenses for use solely in the Field: 
 (i) a perpetual, worldwide, exclusive license, with the limited right to sublicense,
under the following CONKWEST Existing Rights: (x) the CONKWEST Know-How, (y) the CONKWEST Cell Lines, and (z) the CONKWEST Cell Banks; 

(ii) a worldwide, exclusive license, with the limited right to sublicense, for the Term, under the CONKWEST Patents existing as of the
Effective Date; and 
 (iii) a perpetual, worldwide, exclusive, license, without right to sublicense, under the CONKWEST Marks; provided,
however that the license to the CONKWEST Marks is solely for the purpose of promoting, advertising, or marketing BANK 

  
 -8- 

 
products and/or BANK services, including but not limited to the Licensed Products, Licensed Services, and Commercial Products, at the Quality Standards specified in Section 6 hereto; and
further provided, however, that any and all use of the CONKWEST Marks in connection with the BANK products and/or services shall inure to the benefit of CONKWEST. 

The licenses granted in this Section 2(a) expressly exclude the right to reproduce, modify, publicly perform, publicly display, create derivative works
of, or otherwise create derivatives of or improvements to any of the CONKWEST Rights; provided, however, that, subject to the conditions set forth in the following subsections (I) to (III) and to Sections 2(b) and 3 hereto, BANK has the limited
right to modify or otherwise create derivatives of or improvements to the Biological Material and/or the CONKWEST Know-How (the “BANK Modifications”): 

(I) if a given BANK Modification may only be capable of use within the Field (i.e., is not relevant to human or non-human therapeutics) and
BANK is making such BANK Modification internally, without any collaboration or assistance of any sort from a Third Party, then such BANK Modification may be made without CONKWEST’s prior written approval; 

(II) if a given BANK Modification will or may be capable of use outside the Field in connection with human or non-human therapeutics, then
such BANK Modification may be made only upon CONKWEST’s prior written approval, which approval shall not be unreasonably withheld; and 

(III) if BANK proposes to make any BANK Modification in collaboration, assisted by or otherwise with a Third Party, regardless of whether such
BANK Modification is capable of use outside the Field, whether in connection with human or non-human therapeutics or not, then such BANK Modification may be made only upon CONKWEST’s prior written approval, which approval shall not be
unreasonably withheld. Notwithstanding the foregoing, any BANK Modification made in collaboration, assisted by or otherwise with a Third Party, as well as all BANK Intellectual Property pertaining any such BANK Modification, shall be at least
jointly owned by BANK and BANK shall have the right to (and to authorize others, including CONKWEST and its Affiliates (other than BANK) to) use, practice, license, assign and/or otherwise exploit such BANK Modification(s) and/or BANK Intellectual
Property for any purpose without restriction and without the approval of or accounting to any such Third Party. 

  
 -9- 

 The licenses granted to BANK by CONKWEST in this Section 2(a), together with the license granted to BANK by
CONKWEST in Section 2(b) and the sublicense granted to BANK by CONKWEST in Section 2(c), are collectively referred to as the “Licenses.” 

(b) License to BANK Modifications. Subject to the terms and conditions of this Agreement, and subject to Section 3 hereto,
CONKWEST hereby grants to BANK a perpetual, worldwide, exclusive license solely for use in the Field, with the limited right to sublicense, under the BANK Rights. Notwithstanding the license granted in Section 2(a)(i) hereto, CONKWEST hereby
grants to BANK a perpetual, worldwide, limited exclusive license solely for use in the Field, with the limited right to sublicense, under the CONKWEST Cell Lines and the CONKWEST Know-How existing as of the Effective Date, solely for use in
conjunction with the BANK Modifications. 
 (c) Sublicense to FCCC Rights. 

(i) The Parties acknowledge that as of the Effective Date of this Agreement, CONKWEST and its Affiliates are the exclusive licensees of
certain intellectual property rights owned by Fox Chase Cancer Center (the “FCCC Rights”) pursuant to a certain exclusive license between ZelleRx Corporation (CONKWEST’s predecessor in interest) and Fox Chase Cancer Center
dated July 10, 2004 and amended on April 10, 2008 (the “ZelleRx-FCCC License”). The Parties also acknowledge and agree that as of the Effective Date of this Agreement, BANK is an affiliate (as that term is defined in the
ZelleRx-FCCC License) of CONKWEST and therefore also is an exclusive licensee of the FCCC Rights; provided that BANK covenants and agrees only to exercise its license under the FCCC Rights for uses within the Field. 

(ii) In addition, CONKWEST hereby grants to BANK, subject to the terms and conditions of this Agreement, an exclusive sublicense, under
the FCCC Rights, with a limited right to sublicense only to Affiliates of BANK or for the sole purpose of having licensed products (as that term is defined in ZelleRx-FCCC License) made for BANK, in each case, during the term of this Agreement and
solely for use in the Field; provided that 

  
 -10- 

 
BANK shall not exercise the sublicense granted to it under this Section 2(c)(ii) unless and until BANK ceases to be an affiliate (as that term is defined in the ZelleRx-FCCC License) of
CONKWEST. 
 (iii) Notwithstanding any other provision of this Section 2(c), in the event that the ZelleRx-FCCC License terminates, such
sublicense to the FCCC Rights shall automatically terminate effective ninety (90) days following termination thereof without the necessity of notice from FCCC regarding such termination, in which case the Parties acknowledge that, in accordance
with Section 2E of the ZelleRx-FCCC License, FCCC is obligated to negotiate in good faith for a period of ninety (90) days from such termination date to grant a license to BANK under the FCCC Rights. In addition, BANK acknowledges and
agrees that BANK’s exercise of the license under the FCCC Rights as an affiliate of CONKWEST (as described in Section 2(c)(i) above) or as a sublicensee of CONKWEST (as described in Section 2(c)(ii) above) shall, in all cases, be
subject to the terms of the ZelleRx-FCCC License (as such agreement may be amended from time to time after the Effective Date) and BANK agrees to comply, and shall comply, in the exercise of its (sub)license under the FCCC Rights with all terms and
conditions of the ZelleRx-FCCC License applicable to an affiliate or sublicensee of CONKWEST, as the case may be, as if such terms of the ZelleRx-FCCC License were incorporated herein by reference, including without limitation, the following
provisions of the ZelleRx-FCCC License: Sections 2D, 2E, 3F, 6B, 6C, 7B, 10A and 10G. 
 (d) Option to the BANK BIOLOGICS Mark.
Subject to the terms and conditions of this Agreement, CONKWEST hereby grants to BANK, during the term of this Agreement, a first option to acquire the BANK BIOLOGICS Mark, including applications and registrations therefor in the US and abroad,
together with the goodwill of the business symbolized by the BANK BIOLOGICS Mark (the “BANK Option”), the terms of such acquisition to be reasonably negotiated by the Parties within a reasonable time of BANK exercising such BANK
Option. 
 (e) Transfer of Domain Name. CONKWEST hereby transfers (the “Transfer”) to BANK all of its rights, title,
and interest in and to the domain name “www.bankbiologics.com” (the “Domain Name”) and shall, within thirty (30) days of the Effective Date of this Agreement, effectuate such transfer with the registrar of the Domain
Name. 

  
 -11- 

 (f) Sublicense Rights. For purposes of clarity, BANK is entitled to sublicense the rights
granted in Sections 2(a)(i), 2(a)(ii), 2(b), and 2(c) hereto (including the right to distribute the Biological Material) only for use in the Field and to the extent necessary to develop and/or commercialize Commercial Product(s), Licensed Product(s)
and/or Licensed Services, as the case may be; provided, however, that (i) such sublicensee(s) shall not be authorized to grant any further sublicense; (ii) any sublicenses granted by BANK under the FCCC Rights shall be in accordance with
Section 2(c) above and the ZelleRx-FCCC License; and (iii) to the extent any such sublicenses may involve the creation of any BANK Modification, CONKWEST’s prior written approval thereto must be obtained in accordance with
Section 2(a) above. Any sublicenses granted by BANK under the terms of this Agreement shall be subject to terms and conditions that are at least as restrictive as those set forth in this Agreement. BANK shall notify CONKWEST of any sublicense
granted by BANK relating to this Agreement with thirty (30) days thereafter and upon CONKWEST’s request shall provide to CONKWEST a copy of any such sublicense agreement, which copy may be redacted to remove any terms not reasonably
required for the purposes of determining compliance with the terms of this Agreement. For clarity, BANK does not have the right to sublicense the rights granted in Section 2(a)(iii) hereto. 

(g) Licensee and Sublicensee Compliance. BANK will, and will undertake that its Affiliates and sublicensees will, comply with all laws,
rules, regulations and guidelines which apply to the use of the Biological Material, the CONKWEST Know-How, and the CONKWEST Patents, including without limitation, those promulgated by the U.S. Food and Drug Administration (or the foreign local
equivalent), and those relating to the export and import of the Biological Material and the CONKWEST Know-How. 
 (h) Transfer of
Biological Material and Know-How. CONKWEST shall provide the Biological Material to BANK, without charge for handling and delivery therefore, on a date mutually agreeable to both Parties and pursuant to reasonable delivery instructions provided
by BANK to CONKWEST in advance. CONKWEST shall also provide BANK a report (the “CONKWEST Report”) containing CONKWEST Know-How, including instructions on how to work with the Biological Material, no later than the time of the
provision of the Biological Material. The CONKWEST Report shall be regarded at all times as CONKWEST Confidential Information. 

  
 -12- 

 (i) Cooperation by BANK. To the extent reasonably requested from time to time by CONKWEST
or its Affiliates (other than BANK), BANK agrees to discuss in good faith commercially reasonable terms on which BANK may assist CONKWEST or such Affiliate in developing companion diagnostic(s) and/or companion test(s) utilizing the CONKWEST
Existing Rights. 
 3. Ownership; Prosecution/Maintenance; Reservation of Rights; No Additional Rights. 

(a) Ownership of CONKWEST Existing Rights. BANK acknowledges that subject to the licenses or sublicenses, as the case may be, granted to
BANK by CONKWEST in Sections 2(a) and 2(c) hereunder, all right, title and interest in and to the CONKWEST Existing Rights is and shall remain the sole property of CONKWEST. BANK further acknowledges and agrees that, except as expressly permitted
herein, it shall not modify or improve the CONKWEST Existing Rights without the prior written consent of CONKWEST, nor use the CONKWEST Existing Rights for any purpose outside of the Field. 

(b) Ownership of BANK Modifications. BANK and CONKWEST agree that ownership and inventorship with respect to any Intellectual Property
developed hereunder shall be determined according to US laws; provided, however, that subject to the license granted to BANK by CONKWEST under Section 2(b) hereto, all right, title, and interest in and to the BANK Modifications is and shall
remain the sole property of CONKWEST and, to the extent such BANK Modifications are identified, discovered, invented, acquired, and/or developed by BANK (by itself or in collaboration with Third Party(ies)), BANK hereby assigns, and/or shall cause
to be assigned, to CONKWEST all of its right, title, and interest in and to such BANK Modifications. 
 (c) Prosecution/Maintenance.
The Parties shall reasonably cooperate with each other in preparing and filing all appropriate documentation in connection with any patent applications or patents under this Section 3(c). Subject to the terms and conditions of any agreement(s)
with 

  
 -13- 

 
a Third Party regarding the BANK Modifications: 
 (i) CONKWEST shall
consult with BANK to determine in which countries any patent applications related to any BANK Modifications shall be filed, prosecuted, and maintained, including corresponding PCT applications and national phase entry applications, and any and all
patent applications, prosecution, issue and maintenance fees related to any divisional, substitute, reissue, continuation, or extension patents that are based thereon; 

(ii) Unless otherwise agreed in writing, CONKWEST shall pay for any and all fees and costs resulting from drafting, filing,
prosecuting, or maintaining such patents or patent applications related to such BANK Modifications and shall keep BANK reasonably informed on the status of such patents and patent applications; and 

(iii) In the event that CONKWEST decides not to file a patent or patent application described under Section 3(c)(i)
hereto, or decides not to prosecute or maintain any such patent application or patent under Section 3(c)(ii) hereto, then BANK shall have the right, but not the obligation, to file, prosecute, or maintain such patent application or patent, in
which case BANK shall bear all costs and expenses related thereto, beginning on the date that BANK exercises such right and BANK shall keep CONKWEST reasonably informed on the status of any such patents and/or patent applications. 

(iv) Each Party shall cooperate with the other Party in connection with activities relating to the preparation, filing,
prosecution and maintenance of patents and patent applications relating to the BANK Modifications undertaken by the other Party pursuant to this Section 3(c), including: (A) making available to such other Party in a timely manner any
documents or information reasonably necessary or appropriate to facilitate such other Party’s filing, prosecution and maintenance of any such patent or patent application; and (ii) if and as appropriate, signing (or causing to have signed)
all documents relating to the filing, prosecution and maintenance of any such patent or patent application by such other Party. Each Party shall also promptly provide to the other Party all information reasonably requested by such other Party with
regard to such Party’s activities pursuant to this Section 3(c). 

  
 -14- 

 (d) Ownership of Results. Notwithstanding Sections 3(a) and 3(b) hereto, all right, title,
and interest in and to any results and data arising in any part of the world developed by or under the authority of BANK (by itself or in collaboration with or with the assistance of any Third Party) as a result of its use of any or all of the
CONKWEST Existing Rights or the BANK Modifications (collectively, “Results”) shall, as between the Parties, be the exclusive property of BANK and, subject to Section 3(e) hereto, CONKWEST shall have no rights therein. BANK
shall have the unrestricted right to publish or otherwise disclose Results obtained by the practice of the rights granted under this Agreement provided such disclosure does not include any CONKWEST Confidential Information. The name of CONKWEST
shall be given proper recognition in such publication(s) as scientifically appropriate. 
 (e) License to Results. Notwithstanding
Section 3(d), BANK shall provide CONKWEST with a copy of any new Results generated by or under the authority of BANK on a reasonably regular basis during the TERM (but in no event less than once every six (6) months or as otherwise
reasonably requested by CONKWEST). BANK hereby grants CONKWEST a non-exclusive, perpetual, irrevocable, royalty-free, license to use the Results solely for CONKWEST’s internal research purposes and outside the Field. Notwithstanding the
foregoing, it is understood that the license granted by BANK to CONKWEST in this Section 3(e) shall include the right for CONKWEST to authorize a third party conducting research and/or other activities for or on behalf of CONKWEST outside the
Field to use any Results in the performance of such activities . For clarity, such Results shall be considered to be BANK’s proprietary and Confidential Information. Except as specified in this Section 3(e), CONKWEST is expressly
prohibited from disclosing such Results to Third Parties and, to the extent such Results are provided in tangible form, CONKWEST shall not create derivative works thereof or, except for its own internal research purposes, reproduce, display,
distribute, or perform such Results. 
 (f) Reservation of Rights; No Additional Rights. All rights not specifically granted to BANK
herein are expressly reserved by CONKWEST. For the avoidance of doubt, except as expressly set forth in Section 2(a) hereto, BANK is expressly prohibited from reproducing, modifying, publicly performing, publicly displaying, creating derivative
works of, or otherwise creating derivatives of or improvements to any of the CONKWEST Existing Rights or the 

  
 -15- 

 
Biological Material and from Selling, transferring, assigning, or otherwise providing any Third Party access to the CONKWEST Existing Rights or the Biological Material. Nothing contained herein
shall be construed to confer any rights upon either Party by implication, estoppel, or otherwise as to any technology or patent rights of the other Party other than those which are expressly set forth herein. 

4. Manufacture of Licensed Products. CONKWEST shall have the first right, but not the obligation, to manufacture Licensed Products
and/or Commercial Products for BANK, whereby, for each order of Licensed Products, CONKWEST shall notify BANK in writing within thirty (30) days of CONKWEST’s receipt of an order of its decision to manufacture such Licensed Products or
not; provided, however, that BANK may engage a Third Party to manufacture Licensed Products in the event that CONKWEST is unable or unwilling to manufacture and deliver such Licensed Products in the timeframe and/or quantity required by BANK and at
a price agreeable to the Parties, such pricing to be reasonably negotiated. 
 5. Consideration; Payment. 

(a) Royalty Payments. In consideration of the Licenses granted in Section 2 hereto, BANK agrees to pay CONKWEST during the TERM:

  

	 	(i)	a “Royalty” or “Royalties” for the Licensed Products and/or Licensed Services Sold, distributed, or otherwise transferred by BANK and/or its sublicensees, in the amount of three percent
(3%) of the Gross Revenue actually received by BANK and/or its sublicensees therefor; 

  

	 	(ii)	a “Royalty” or “Royalties” for the Sale of Commercial Products by BANK and/or its sublicensees in the amount of three percent (3%) of the Gross Revenue actually received by BANK
and/or its sublicensees therefor; and/or 

  

	 	(iii)	BANK shall pay CONKWEST five percent (5%) of any Sublicensing Revenue actually received by BANK. 

  
 -16- 

	 	(iv)	All amounts necessary to reimburse CONKWEST for amounts payable by CONKWEST under the ZelleRx-FCCC License as a result of or arising from BANK’s exercise of the rights granted to it under the FCCC Rights pursuant
to this Agreement. 

 BANK (itself or by or through its permitted sublicensees and/or other contractors) shall take all commercially
reasonable steps to develop, commercialize, and promote the sales of Licensed Products, Licensed Services and/or Commercial Products. BANK will have no obligation to pay CONKWEST a “Minimum Annual Royalty” on any Commercial Products,
Licensed Products or Licensed Services. 
 All Royalties and other amounts due pursuant to this Section 5(b) for a particular calendar quarter shall be
due and payable by BANK to CONKWEST in U.S. dollars within thirty (30) days following the end of such calendar quarter. With each payment, BANK shall provide a written statement setting forth the total Gross Revenue and Sublicensing Revenues
for the applicable calendar quarter and such other information as CONKWEST may reasonably request in order to verify the calculation of payments made by BANK to CONKWEST under this Agreement or to satisfy CONKWEST’s reporting obligations under
the ZelleRx-FCCC License. 
 (c) Method of Payment. All payments to CONKWEST hereunder shall be made payable to CONKWEST and sent to
the address identified in Section 13 or remitted to CONKWEST’s account at a bank in the United States to be designated by CONKWEST in writing and sent to BANK in advance of such payment. 

(d) Third-Party Payments. Subject to Section 5(a)(iv) above, CONKWEST is responsible for all payments, if any, to Third Parties
that are owed pursuant to any agreement executed by CONKWEST prior to the Effective Date as a result of BANK exercising the Licenses granted by CONKWEST to BANK herein in accordance with the terms and conditions of this Agreement. Notwithstanding
the foregoing, BANK is responsible for obtaining, at its expense, any Third Party intellectual property required to utilize, practice or otherwise perform under the Licenses granted herein, including the development and commercialization of its
products, including the Commercial Products, Licensed Products and/or Licensed Services. 

  
 -17- 

 (e) Payments in U.S. Dollars. All payments due hereunder are payable in United States
dollars. 
 (f) Taxes: 

(i) All payments due hereunder are inclusive of all applicable Taxes subject however to Section 3(f)(ii) below. If any
such Taxes are chargeable in respect of any payments, BANK shall pay such Taxes at the applicable rate in respect of any such payments following the receipt, where applicable, of a Taxes invoice in the appropriate form issued by CONKWEST in respect
of those payments. The applicable Taxes shall be payable on the due date of the payment to which such Taxes relate. 
 (ii)
BANK may deduct withholding Taxes from the payment it owes CONKWEST under this Agreement. BANK will, on behalf of CONKWEST, pay the withheld Tax to the appropriate authority and provide CONKWEST with proof of payment and evidence of the tax
obligation. BANK will at CONKWEST’s request and expense provide CONKWEST reasonable assistance in recovering these withholding Taxes. 

(g) Maintenance of Records. BANK shall keep accurate records of all of its operations and of reports of operations by its sublicensees
within the scope of this Agreement. CONKWEST, at its sole expense, shall have the right to have a Certified Public Accountant of its choice inspect such records at BANK’s office for two years after the calendar year to which they pertain at
reasonable times upon two (2) weeks prior written notice by CONKWEST. In addition, and without limiting the foregoing, BANK shall comply with the record keeping and auditing requirements of the ZelleRx-FCCC License, as communicated by CONKWEST
to BANK reasonably in advance. 
 6. Quality Standards. 

(a) In order to carry out the rights granted in Section 2(a)(iii) hereto, BANK is authorized to use the CONKWEST Marks in such style,
appearance and manner as CONKWEST shall, in its sole discretion, specify or approve in writing and solely on or in association with products and/or services in the Field and in strict accordance with all of the applicable Quality

  
 -18- 

 
Standards. BANK may not manufacture, sell, promote, or distribute any product or service to be used in association with the CONKWEST Marks, including but not limited to the Licensed Products and
Licensed Services, until it has obtained the requisite written approvals from CONKWEST. It is within CONKWEST’s sole reasonable discretion to grant or withhold any approval. BANK further understands that it is an essential condition of the
validity of this Agreement, of the validity of the CONKWEST Marks licensed herein, and for the protection of the high reputation enjoyed by CONKWEST, that the products and services produced in association with any of the CONKWEST Marks be of high
and consistent quality subject to the on-going approval and continuing supervision and control of CONKWEST. 
 (b) BANK is expressly
prohibited from modifying the CONKWEST Marks unless expressly agreed to and such modifications are expressly approved in writing by CONKWEST. 

(c) BANK will not use the CONKWEST Marks in conjunction or association with any other trademark, trade name, or logo, or place the CONKWEST
Marks in close proximity to any other name, mark or logo without the express prior written approval of CONKWEST. 
 (d) BANK will comply as
soon as reasonably practicable (but in any event within twenty days) with all reasonable instructions furnished by CONKWEST from time-to-time with respect to the style, appearance and manner of use of the CONKWEST Marks on or in connection with the
products and/or services, including instructions to revise the style, appearance or manner of use as CONKWEST may specify from time to time. 

(e) Whenever the CONKWEST Marks are used on or in connection with the products and/or services, BANK shall use the trademark symbol
“TM”, the service mark symbol “SM”, or the registration symbol “®”, as appropriate. 

7. Infringement by Third Parties. 

(a) Notice. If any of the CONKWEST Existing Rights or the BANK Modifications are infringed and/or misappropriated by a Third Party, the
Party first having knowledge of such infringement and/or misappropriation shall promptly notify the other Party in writing. The notice shall set forth the facts of such infringement and/or misappropriation in reasonable detail. 

  
 -19- 

 (b) Infringement Actions; CONKWEST Rights/BANK Modifications. CONKWEST shall have the sole
and exclusive right, but not the obligation, to institute, litigate and control any claim, action or proceeding with respect to any infringement and/or misappropriation by a Third Party (an “Infringement Action”) of any of the CONKWEST
Existing Rights or the BANK Modifications, by counsel of its own choice, in which case BANK shall reasonably cooperate with CONKWEST at CONKWEST’s request and expense in the litigation of such Infringement Action; provided, however, that BANK
shall not be obligated to join in any such Infringement Action related to the CONKWEST Existing Rights or the BANK Modifications (subject to ownership of the BANK Modifications) except to the extent necessary for standing purposes. CONKWEST shall be
entitled to make all decisions with respect to control of litigation, settlement, consent judgment or other voluntary final disposition of an Infringement Action regarding the CONKWEST Existing Rights and/or the BANK Modifications; provided that
CONKWEST shall have no right or authority to bind BANK with respect to any such matters without BANK’s express prior written consent; and provided, however, that CONKWEST’s rights and obligations under this Section 7(b) with respect
to the BANK Modifications are subject to the terms and conditions of any agreement(s) with a Third Party with whom BANK collaborated to identify, discover, invent, acquire, and/or develop such BANK Modifications. 

8. Representations and Warranties. 
 (a)
Each Party hereby represents and warrants to the other Party as of the Effective Date that: 
 (i) it is a corporation duly
organized, validly existing and in good standing under the laws of the jurisdiction in which it is incorporated; 
 (ii) it
has the corporate power and authority and the legal right to enter into this Agreement free from any conflicting right owed to a Third Party and to perform its obligations hereunder; 

(iii) it has taken all necessary corporate action on its part to authorize the execution and delivery of this Agreement and the
performance of its obligations hereunder and that this Agreement has been duly executed and delivered on behalf of each Party, and constitutes a legal, valid, binding obligation, enforceable against such Party in accordance with its terms; 

  
 -20- 

 (iv) all necessary consents, approvals and authorizations of all applicable
competent authorities and other persons required to be obtained by such Party in order to execute this Agreement on behalf of such Party have been obtained; and 

(v) the execution and delivery of this Agreement and the performance of such Party’s obligations do not constitute a
default or require any consent under any other contractual obligation of such Party. 
 (b) CONKWEST hereby represents and warrants to BANK
that as of the Effective Date: 
 (i) CONKWEST owns and controls within the Field the CONKWEST Existing Rights, and has
obtained all necessary assignments, licenses, and other rights in and to the CONKWEST Existing Rights necessary to provide to BANK the Biological Material and CONKWEST Know-How and grant the Licenses as described herein; 

(ii) CONKWEST has the sole and exclusive right to grant to BANK the Licenses, Option, and Transfer set out in this Agreement;
and 
 (iii) CONKWEST has not previously entered into any agreement, whether written or oral, with respect to the CONKWEST
Existing Rights which conflicts with the rights granted to BANK hereunder and will not enter into any such agreement during the Term of this Agreement. 

(c) BANK hereby represents and warrants to CONKWEST that: 

(i) BANK will not attend any meetings with regulatory agencies that relate to the CONKWEST Existing Rights unless it is
accompanied by a representative of CONKWEST or CONKWEST agrees in writing that BANK may attend such meetings in the absence of CONKWEST; 

  
 -21- 

 (ii) BANK shall not, and shall not collude with, authorize or assist any Third
Party to, use any of the CONKWEST Existing Rights or any of the BANK Modifications outside of the Field; 
 (iii) BANK shall
not, and shall not collude with, authorize or assist any Third Party to, take any action to intentionally compete, directly or indirectly, with CONKWEST outside of the Field; and 

(iv) BANK shall not, and shall not collude with, authorize or assist any Third Party to, distort, misuse, diminish, infringe,
dilute, contest or challenge CONKWEST’s rights in and to, ownership of, and registrations or applications for registration of, CONKWEST’s Existing Rights or the BANK Modifications. 

9. Indemnification. 
 (a)
CONKWEST shall indemnify, defend and hold harmless BANK and its Indemnitees from and against any and all claims, losses, demands, liabilities, judgments, actions, causes of action, costs and expenses, of any type or kind (including reasonable
attorneys’ fees) (collectively “Claims”) brought by a Third Party, if the Claims: 
 (i) result from a
breach of CONKWEST’s representations and warranties under Section 8 hereinabove; 
 (ii) result from a material
breach by CONKWEST of the terms of this Agreement; or 
 (iii) result from a claim that the CONKWEST Existing Rights infringe
the intellectual property of a Third Party; 
 provided, however, that CONKWEST shall not be obligated to indemnify BANK and its Indemnitees
under this Section 9(a) to the extent the Claims are a result of negligence or willful misconduct of BANK or its Indemnitees or a matter with respect to which BANK is obligated to indemnify CONKWEST pursuant to Section 9(b) below, and
provided further, that CONKWEST’s liability to indemnify BANK or its indemnities under this Section 9(a) shall not exceed the amounts paid by BANK to CONKWEST hereunder. 

  
 -22- 

 (b) BANK shall indemnify, defend and hold harmless CONKWEST and its Indemnitees from and against
any and all Claims brought by a Third Party, if the Claims: 
 (i) result from a breach of BANK’s representations and warranties under
Section 8 hereinabove; 
 (ii) result from the material breach by BANK of the terms of this Agreement or any terms of
the ZelleRx-FCCC License applicable to BANK in its capacity as an affiliate (as defined in the ZelleRx-FCCC License) of CONKWEST or CONKWEST’s sublicensee; 

(iii) result from the development, commercialization, Sale, distribution or use of a Licensed Product, Licensed Service, and/or
Commercial Product by or under the authority of BANK or its sublicensees; 
 (iv) result from any use of the Biological
Material or CONKWEST Know-How by BANK or its sublicensees (other than claims that the CONKWEST Cell Lines infringe the intellectual property rights of a Third Party); or 

(v) result from a claim that the BANK Modifications infringe the intellectual property of a Third Party; 

provided, however, that BANK shall not be obligated to indemnify CONKWEST and its Indemnities under this Section 9(b) to the extent the
Claims are a result of negligence or willful misconduct of CONKWEST or its Indemnitees or a matter in respect of which CONKWEST is obligated to indemnify BANK pursuant to Section 9(a) above. 

(c) In order to maintain the right to be covered under Section 9(a) or (b), the Indemnitee must: (i) promptly notify the
indemnifying Party (“Indemnitor”) in writing after learning of any Claims; (ii) allow the Indemnitor to manage and control (by way of intervention or otherwise) the defense and settlement of any such Claims against the
Indemnitees; (iii) cooperate with the Indemnitor in the defense or the settlement negotiation of Claims reasonably required by the Indemnitor; and (iv) abstain from making any statements or taking any actions which damage the defense
against any Claims (including, without limitation, any statements against the interest of 

  
 -23- 

 
the Indemnitees or admissions of causation or guilt). The Indemnitor shall not agree to any settlement that adversely affects the Indemnitees’ rights or interests without the
Indemnitees’ prior written approval (which approval shall not be unreasonably withheld). The Indemnitor will not be responsible for any costs or expenses (including attorney fees) incurred or made by the Indemnitees without Indemnitor’s
prior written consent, and then only to the extent they are reasonable. The Indemnitees may retain its or their own legal counsel to monitor an indemnification event, but the Indemnitees shall be responsible for its own costs and expenses with
respect thereto, subject to the preceding sentence. 
 (d) Disclaimer of Warranties. EXCEPT AS SPECIFICALLY STATED IN SECTION 8
ABOVE, CONKWEST MAKES NO REPRESENTATIONS AND EXTENDS NO WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED. WARRANTIES DISCLAIMED INCLUDE, BUT ARE NOT LIMITED TO, ANY EXPRESS OR IMPLIED WARRANTIES OF DESIGN, MERCHANTABILITY OR FITNESS FOR A
PARTICULAR PURPOSE; OR ARISING FROM A COURSE OF DEALING, USAGE OR TRADE PRACTICE. 
 (e) Limitations of Liability. IN NO EVENT WILL
EITHER PARTY BE LIABLE FOR ANY LOST REVENUES, LOST PROFITS, OR OTHER INCIDENTAL, SPECIAL, INDIRECT OR CONSEQUENTIAL DAMAGES ARISING OUT OF THIS AGREEMENT OR ITS PERFORMANCE OR BREACH, EVEN IF THEY HAVE BEEN ADVISED OF THE POSSIBILITY OF SUCH
DAMAGES; PROVIDED THAT THE FOREGOING LIMITATION OF LIABILITY SHALL NOT APPLY TO LIMIT A PARTY’S DAMAGES IN THE EVENT OF (A) THE OTHER PARTY’S BREACH OF ITS CONFIDENTIALITY OBLIGATIONS UNDER SECTION 10 BELOW, (B) THE USE BY OR
UNDER THE AUTHORITY OF BANK OF ANY OF THE CONKWEST EXISTING RIGHTS OR BANK MODIFICATIONS OUTSIDE IN THE FIELD IN BREACH OF THIS AGREEMENT OR (C) ANY BREACH BY BANK OF SECTION 2(c) ABOVE. FOR THE AVOIDANCE OF DOUBT, DIRECT FINANCIAL OR
OTHER LOSSES, INCLUDING LOSSES RESULTING FROM BANK’S BREACH OF THE SCOPE OF THE LICENSES, ARE EXCLUDED FROM THIS PROVISION. 

  
 -24- 

 (f) The provisions of this Section shall survive termination. 

10. Confidentiality. 
 (a) Each Party,
with respect to the other Party’s Confidential Information: 
 (i) may only use the Confidential Information for the
purposes envisaged under this Agreement; 
 (ii) must ensure that only those of its officers, employees, sublicensees and
Third Parties working with, for and/or on behalf of such Party who are directly concerned with carrying out the purposes envisaged under this Agreement have access to the Confidential Information on a strictly applied “need to know” basis,
are informed of the secret and confidential nature of it, and have entered into written agreements, prior to such disclosure, obligating them to hold in confidence and not use any Confidential Information except as permitted by this Agreement; 

(iii) must keep the Confidential Information secret and confidential and not disclose or permit to be disclosed, make available
or permit to be made available the same to any Third Party for any reason without the prior written consent of the disclosing Party or except as set forth in this Agreement; and 

(iv) must not copy, reproduce or otherwise replicate for any purpose or in any manner whatsoever any documents containing the
Confidential Information except as necessary to exercise the rights granted it and/or in the performance of its obligations under this Agreement. 

(b) The obligations of confidence referred to in Section 10(a) shall not extend to any Confidential Information which: 

(i) is or becomes generally available to the public otherwise than by reason of breach by a recipient Party of the provisions
of this Agreement; 

  
 -25- 

 (ii) is known to the recipient Party and is at its free disposal prior to its
receipt from the disclosing Party provided that evidence of such knowledge is proven by competent written records; 
 (iii)
is subsequently disclosed to the recipient Party without obligations of confidence by a Third Party owing no such obligations to the disclosing Party in respect of that Confidential Information; 

(iv) is independently developed by a Party without reliance on the Confidential Information of the other Party, provided that
evidence of such is proven by competent written records; or 
 (v) is required to be disclosed in order to comply with any
law, regulation or valid court order (including, without limitation, as part of any regulatory submission or approval process) to the extent necessary for such compliance; provided, however, the Party seeking such disclosure shall provide prompt
written notice of this requirement to the disclosing Party in order to provide the disclosing Party an opportunity to seek appropriate relief to prevent or limit such disclosure, provided always that in such circumstances such disclosure shall be
only to the extent so required and shall be subject to reasonable prior consultation with the disclosing Party with a view to agreeing to the timing and content of such disclosure, or other such equitable relief and shall reasonably cooperate with
such other Party’s efforts to seek confidential treatment of any Confidential Information to be disclosed. 
 (c) All Confidential
Information owned by and disclosed by the disclosing Party to the recipient Party shall remain the property of the disclosing Party. In the event that a court or competent authority assumes partial or complete control over the assets of a recipient
Party based on the insolvency or bankruptcy of that Party, the recipient Party shall promptly notify such court or competent authority that (i) Confidential Information received from the disclosing Party under this Agreement remains the
property of the disclosing Party; and (ii) of the confidential obligations under this Agreement; and to the extent permitted by law, take all steps reasonably necessary to maintain the confidentiality and security of the disclosing Party’s
Confidential Information to ensure that the court or competent authority maintains that Confidential Information in confidence in accordance with this Agreement. 

  
 -26- 

 (d) The obligations of the Parties under Section 10 shall last until the Confidential
Information is no longer secret and confidential through no breach of any provision of this Agreement. 
 (e) The requirement under
Section 10(b)(v) to notify the disclosing Party when Confidential Information is required to be disclosed by law shall not apply when such disclosure is required as part of any regulatory submission or approval process. 

(f) Each Party agrees not to disclose to any Third Party the terms of this Agreement without the prior written consent of the other Party
hereto, except each Party may disclose the terms of this Agreement: (i) to advisors (including financial advisors, attorneys and accountants), actual or potential sublicensees, acquisition partners or investors, and others on a need to know
basis, in each case under appropriate confidentiality provisions substantially equivalent to those in this Agreement; or (ii) to the extent necessary to comply with applicable laws and court orders, including securities laws, regulations or
guidances; provided that in the case of paragraph (ii) the disclosing Party shall promptly notify the other Party and (other than in the case where such disclosure is reasonably necessary to comply with securities laws, regulations or
guidances) allow the other Party a reasonable opportunity to oppose with the body initiating the process and, to the extent allowable by law, to seek limitations on the portion of the Agreement that is required to be disclosed. 

11. Term; Termination. 
 (a) This
Agreement shall come into force on the Effective Date and: 
 (i) with respect to the licenses granted in Sections 2(a)(i),
2(a)(iii), and 2(b) shall remain in full force and effect perpetually, unless terminated as herein provided; 
 (ii) with
respect to the license granted in Section 2(a)(ii), shall remain in full force and effect, unless earlier terminated as herein provided, until the last-to-expire Valid Claim (the “Term”), at which time such license shall be
fully paid up and perpetual, unless terminated as herein provided; and 

  
 -27- 

 (iii) with respect to the sublicense granted in
Section 2(c) shall remain in full force and effect for as long as the ZelleRx-FCCC License remains in full force and effect. 

(b) Termination for Insolvency. 

(i) If voluntary or involuntary proceedings by or against a Party are instituted in bankruptcy under any insolvency law, or a
receiver or custodian is appointed for such Party, or proceedings are instituted by or against such Party, in each of the foregoing cases only if it is for dissolution of such Party, which proceedings, if involuntary, shall not have been dismissed
within sixty (60) days after the date of filing, then this Agreement may be terminated by the other Party. 
 (ii)
Notwithstanding Section 3(b), all rights and licenses granted under this Agreement are, and shall be deemed to be, for purposes of Section 365(n) of the United States Bankruptcy Code, licenses of rights to “intellectual property”
as defined under Section 101(35A) of the United States Bankruptcy Code. In the event of the commencement of a bankruptcy proceeding by or against a Party under the United States Bankruptcy Code, the other Party shall be entitled to complete
access to any such intellectual property licensed to it hereunder, and all embodiments of such intellectual property, but only as necessary for the purposes of exploitation of the licenses granted to the non-affected party under this Agreement and
subject to payment of the applicable fees (if any) set forth in this Agreement through the effective date of any termination hereunder. 

(c) Either Party has the right, upon sixty (60) days prior written notice to the other Party, to terminate this Agreement, including all
licenses hereunder, if such other Party is in breach of its material obligations hereunder and has not cured such breach within sixty (60) days after receipt of written notice requesting cure of the breach. Notwithstanding the foregoing, if the
Party alleged to be in breach disputes such any allegation of material breach in writing within the applicable sixty (60) day period, the affected Party shall not have the right to terminate this

  
 -28- 

 
Agreement unless and until it is finally determined by arbitration conducted in accordance with Section 24 below that such material breach was committed by such Party, and such Party fails
to cure such material breach within sixty (60) days after such determination. 
 (d) BANK has the right, upon sixty (60) days
prior written notice to CONKWEST, to terminate this Agreement for any reason or no reason, including any or all Licenses granted by CONKWEST hereunder. 

(e) CONKWEST shall have the right to terminate this Agreement upon notice to BANK in the event that BANK, or any of its sublicensees, or any
Third Party assigned or designated by BANK, or any of its sublicensees, takes any action, directly or indirectly, or knowingly provides financial or other assistance, including legal or technical advice, directly or indirectly, to any Third Party to
challenge to the validity, enforceability, scope, inventorship or ownership of any of the CONKWEST Patents or any patent rights included within the FCCC Rights in any court or tribunal or before the United States Patent and Trademark Office or any
patent office in a jurisdiction outside of the United States, or in any arbitration proceeding, including in connection with an opposition proceeding or re-examination, and within thirty (30) days after written notice thereof by CONKWEST, BANK
does not withdraw or cause to be withdrawn such action; provided, however, that CONKWEST shall not have such right to terminate this Agreement if such action is taken with respect to a CONKWEST Patent that has been asserted against BANK, or any of
its sublicensees, in a legal, court, administrative or other governmental proceeding. 
 (f) In the event of termination of this Agreement
by CONKWEST under subsections (c) or (e) above or by BANK under subsection (d) above, the Licenses granted hereunder shall terminate, BANK will destroy the Biological Material and the CONKWEST Cell Lines and destroy all CONKWEST
Confidential Information provided by CONKWEST to BANK hereunder within thirty (30) days following termination under such subsection, and BANK specifically agrees to make no further use of the CONKWEST Existing Rights or the BANK Modifications
for any purpose. For the avoidance of doubt, in the event of any such termination, the licenses and rights granted by BANK to CONKWEST hereunder shall survive. 

  
 -29- 

 12. Assignment; Successors. This Agreement including the rights and privileges granted hereunder may not
be assigned by either Party without the prior written consent of the other Party; provided, however, that either Party may, without the other Party’s consent, assign this Agreement and its rights and obligations hereunder (a) to an
Affiliate or (b) in connection with the transfer or sale of all or substantially all of its business or assets, or in the event of its merger, consolidation, change in control or other similar transaction. This Agreement is binding upon and
will inure to the benefit of the Parties and their respective successors and permitted assigns. 
 13. Notice Address. Any payment, notice or other
communication pursuant hereto shall be sufficiently made or given if sent to the other Party by certified or registered mail postage prepaid, facsimile, or sent by nationally-recognized overnight courier addressed to it at its address below or at
such other address as a Party may later designate by written change of address notice given to the other Party in accordance with this Section 13. Any such notice shall be deemed to have been given: (a) when delivered if sent by facsimile
on a business day (or if delivered or sent on a non-business day, then on the next business day); (b) on the business day after dispatch if sent by nationally-recognized overnight courier; or (c) on the fifth (5th) business day
following the date of mailing, if sent by mail. 
 If to CONKWEST: 

CONKWEST Incorporated 
 2533 South Coast Highway 101 

Suite 210 
 Cardiff-By-The-Sea, CA 92007-2133 

Attention: Barry J. Simon, M.D., 
 President & CEO

 Telephone: (858) 633-0300 
 Facsimile:
(858) 380-1999 
 E-mail: bsimon@conkwest.com 
 With
copies to: 
 Pietragallo Gordon Alfano Bosick & Raspanti, LLP 

38th Floor, One Oxford Centre 
 Pittsburgh, PA 15219 

Attention: Alicia M. Passerin, Ph.D, Esq. 
 Telephone: (412)
263-4369
 Facsimile: (412) 261-0915 
 E-mail:
AMP@Pietragallo.com 

  
 -30- 

 If to BANK: 
 BANK
Biologics 
 2533 South Coast Highway 101 
 Suite 210 

Cardiff-By-The-Sea, CA 92007-2133 
 Attention: Chief Executive
Officer 
 Telephone: (858) 633-0300 
 Facsimile:
(858) 380-1999 
 Email:
                                         

 

	14.	Headings. All headings are for convenience only and shall not affect the meaning of any provision hereof. 

15. Force majeure. If a Party (the “Non-Performing Party”) is unable to carry out any of its obligations under this Agreement due to
Force Majeure, this Agreement shall remain in effect but the Non-Performing Party’s relevant obligations under this Agreement and the corresponding obligations of the other Party (the “Innocent Party”) under this Agreement,
shall be suspended for a period equal to the circumstance of Force Majeure, provided that: 
 (a) the suspension of performance is of no
greater scope than is required by the Force Majeure; 
 (b) the Non-Performing Party gives the Innocent Party written notice describing the
circumstance of Force Majeure as soon as reasonably practical, including the nature of the occurrence; 
 (c) the Non-Performing Party uses
all reasonable efforts to remedy its inability to perform and to mitigate the effects of the circumstance of Force Majeure; and 
 (d) as
soon as practicable after the event which constitutes Force Majeure the Parties discuss how best to continue their operations as far as possible in accordance with this Agreement. 

  
 -31- 

 16. Entire Agreement. This Agreement, together with any Appendices attached hereto and specifically
referenced herein, contains the entire understanding of the Parties with respect to the subject matter herein and supersedes all previous agreements and undertakings with respect thereto. 

17. Miscellaneous: This Agreement may be amended only by a writing signed by the authorized representative of each of the Parties.  

18. Survival: The expiration or termination of this Agreement for any reason shall not release either Party from any liability that, at the time
of such expiration or termination, has already accrued to the other Party or that is attributable to a period prior to such expiration or termination, nor will any termination of this Agreement preclude either Party from pursuing all rights and
remedies it may have under this Agreement, or at law or in equity, with respect to any breach of this Agreement. In addition, the following provisions of the Agreement shall survive expiry or any termination of the Agreement: Sections 1, 2(b), 3,
5(g), 9, 10,11, 13, 14, this Section 18, 19, 20, 21, and 24 and all definitions relating to the foregoing.  
 19. Governing Law:
This Agreement shall be construed in accordance with the laws of the State of Delaware, and the patent laws of the United States, without regard or reference to any of its rules or provisions governing conflict of laws.  

20. Severance of Terms: If the whole or any part of this Agreement is or becomes or is declared illegal, invalid or unenforceable in any
jurisdiction for any reason (including both by reason of the provisions of any legislation and also by reason of any decision of any court or competent authority which either has jurisdiction over this Agreement or has jurisdiction over any of the
Parties): 
 (a) in the case of the illegality, invalidity or unenforceability of the whole of this Agreement it shall terminate in
relation to the jurisdiction in question; or 
 (b) in the case of the illegality, invalidity or unenforceability of part of this Agreement
that part shall be severed from this Agreement in the jurisdiction in question and that illegality, invalidity or unenforceability shall not in any way whatsoever prejudice or affect the remaining parts of this Agreement which shall continue in full
force and effect unless the 

  
 -32- 

 
absence of the invalidated, illegal or unenforceable provisions(s) adversely affects the substantive rights of the Parties. The Parties shall in such an instance use their reasonable good faith
efforts to replace the invalid, illegal or unenforceable provision(s) with valid, legal and enforceable provision(s) which, insofar as practical, implement the purposes of this Agreement. 

21. Waiver. The waiver by a Party of any right hereunder, or of any failure of the other Party to perform, or of any breach or violation of any
provision hereof by the other Party shall not operate or be construed a waiver of any other right hereunder or of any other subsequent failure, breach or violation of such other Party hereof whether of a similar nature or otherwise. 

22. Export. It is understood that the Biological Material and Know-How provided or made available by CONKWEST under this Agreement may be subject to
applicable laws and regulations controlling the export and import of technical data, biological materials, laboratory prototypes, and other information or materials that may require a license from the applicable agency of the United States
Government or foreign government, and BANK will comply with all such laws and regulations in the performance of this Agreement. CONKWEST neither represents that a license will not be required nor does CONKWEST represent that if a license is
required, it will be issued. 
 23. Counterparts; Telefacsimile, Electronic Execution. This Agreement may be executed in any number of counterparts
(facsimile and electronic transmission included), and by each of the Parties on separate counterparts, each of which, when so executed, shall be deemed an original, but all of which shall constitute but one and the same instrument. After facsimile
or electronic transmission, the Parties agree to execute and exchange documents with original signatures. 
  

	24.	Dispute Resolution. 

 (a) The Parties shall negotiate in good faith and use reasonable
efforts to settle any dispute, controversy or claim arising from or related to this Agreement or the performance or breach thereof. If the Parties do not fully settle, and a Party wishes to pursue the matter, each such dispute, controversy or claim
that is not an “Excluded Claim” shall be finally resolved by binding arbitration in accordance with the Commercial Arbitration Rules and Supplementary Procedures for Large Complex Disputes of the American Arbitration Association
(“AAA”), and judgment on the arbitration award may be entered in any court having jurisdiction thereof. 

  
 -33- 

 (b) The arbitration shall be conducted by a panel of three persons experienced in the
pharmaceutical business: within thirty (30) days after initiation of arbitration, each Party shall select one person to act as arbitrator and the two Party-selected arbitrators shall select a third arbitrator within thirty (30) days of
their appointment. If the arbitrators selected by the Parties are unable or fail to agree upon the third arbitrator, the third arbitrator shall be appointed by the AAA. The place of arbitration shall be San Diego, California, and all proceedings and
communications shall be in English. 
 (c) Either Party may apply to the arbitrators for interim injunctive relief until the arbitration
award is rendered or the controversy is otherwise resolved. Either Party also may, without waiving any remedy under this Agreement, seek from any court having jurisdiction any injunctive or provisional relief necessary to protect the rights or
property of that Party pending the arbitration award. The arbitrators shall have no authority to award punitive or any other type of damages not measured by a Party’s compensatory damages. Each Party shall bear its own costs and expenses and
attorneys’ fees and an equal share of the arbitrators’ fees and any administrative fees of arbitration. 
 (d) Except to the
extent necessary to confirm an award or as may be required by law, neither a Party nor an arbitrator may disclose the existence, content, or results of an arbitration without the prior written consent of both Parties; provided that either Party may
make such disclosures as are permitted for Confidential Information of the other Party under Section 10 above. In no event shall an arbitration be initiated after the date when commencement of a legal or equitable proceeding based on the
dispute, controversy or claim would be barred by the applicable Delaware statute of limitations. 
 (e) The Parties agree that, in the event
of a good faith dispute over the nature or quality of performance under this Agreement, neither Party may terminate this Agreement until final resolution of the dispute through arbitration or other judicial determination. The Parties further agree
that any payments made pursuant to this Agreement pending resolution of the dispute shall be refunded if an arbitrator or court determines that such payments are not due. 

  
 -34- 

 (f) As used in this Section, the term “Excluded Claim” means a dispute,
controversy or claim that concerns (a) the validity or infringement of a patent, trademark or copyright; or (b) any antitrust, anti-monopoly or competition law or regulation, whether or not statutory; or (c) the misappropriation of
any trade secret or breach of confidentiality obligation under this Agreement. 
 SIGNATURE PAGE FOLLOWS 

  
 -35- 

 SIGNATURE PAGE TO NON-EXCLUSIVE LICENSE AGREEMENT 

IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed by their duly authorized representatives. 

 

									
	CONKWEST INCORPORATED:				BRINK BIOLOGICS, INC. (dba BANK BIOLOGICS)
					
	By:		 /s/ Barry J. Simon
				By:		 /s/ Barry J. Simon

	Name:		Barry J. Simon, M.D.				Name:		Barry J. Simon, M.D.
	Title:		President and COO				Title:		President and CEO
	Date:		June 9, 2015				Date:		June 9, 2015

 SCHEDULE A 

[***] 

 APPENDIX B 

CONKWEST KNOW-HOW 

[***] 

 SCHEDULE C 

CONKWEST MARKS 
 [***]

 SCHEDULE D – FCCC Patents and Patent Applications 

[***]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00246-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00246-of-00352.parquet"}]]